GWG Holdings, Inc. (Form: 10-Q, Received: 08/08/2014 14:48:09)

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

You should read the following discussion in conjunction with the consolidated financial statements and accompanying notes and the information contained in other sections of this report. This discussion and analysis is based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. The statements in this discussion and analysis and elsewhere in this report, concerning expectations regarding our future performance, liquidity and capital resources, as well as other non-historical statements, are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties. Our actual results could differ materially from those suggested or implied by any forward-looking statements.

Overview

We are engaged in providing financial services in the emerging secondary market for life insurance policies. Our financial service offerings are targeted towards consumers owning life insurance who can benefit from the actuarial value of their life insurance policy. To date, our primary financial service has been to offer consumers the ability to sell their policy for cash. In addition, we have offered investors the opportunity to participate in our business through a series of debt offerings. We are in the process of expanding the services we offer consumers who own life insurance by offering them options such as to retain a portion of their policy benefits or to exchange their life insurance for a more desirable asset. All of the services we offer are based upon acquiring, or otherwise financing, life insurance policy benefits from consumers in the secondary market at a discount to the face value of the insurance benefit. Once we purchase or finance a policy benefit at a discount, we continue paying the policy premiums in order to ultimately collect the face value of the insurance benefit. We seek to hold the policies to maturity, in order to ultimately collect the policy’s benefit upon the insured’s mortality. Our strategy is to build a profitable (purchased at discounts sufficient to provide a positive return on investment) and large (greater than 300 lives) portfolio of policies that are well diversified in terms of insurance carriers and the mortality profiles of insureds. We believe that diversification among insurers, mortality profiles, and medical conditions will lower our overall risk exposure, and that a larger number of policies (diversification in overall number) will provide our portfolio with greater actuarial stability.

In the first six months of 2014, we recognized $231,000 of revenue from the receipt of $300,000 in policy benefits. In addition, we recognized revenue from the change in fair value of our life insurance policies, net of premiums and carrying costs, of $10,770,000. Interest expense, including amortization of the deferred financing costs and preferred stock dividends, was $12,935,000 for the six months ended June 30, 2014, and selling, general and administrative expenses for the six months ended June 30, 2014 were $4,840,000. Income tax benefit for the six months ended June 30, 2014 was $2,272,000. Our net loss for the six months ended June 30, 2014 was $4,488,000.

Critical Accounting Policies

Critical Accounting Estimates

The preparation of our consolidated financial statements in accordance with the Generally Accepted Accounting Principles (GAAP) requires us to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We base our judgments, estimates and assumptions on historical experience and on various other factors believed to be reasonable under the circumstances. Actual results could differ materially from these estimates. We evaluate our judgments, estimates and assumptions on a regular basis and make changes accordingly. We believe that the judgments, estimates and assumptions involved in the accounting for the valuation of investments in life insurance policies have the greatest potential impact on our consolidated financial statements and accordingly believe these to be our critical accounting estimates. Below we discuss the critical accounting policies associated with these estimates as well as certain other critical accounting policies.

Ownership of Life Insurance Policies—Fair Value Option

Our primary business involves the purchasing and financing of life insurance policies. As such, we account for the purchase of life insurance policies in accordance with Financial Accounting Standards Board’s Accounting Standards Codification (FASB ASC) 325-30, Investments in Insurance Contracts , which requires us to use either the investment method or the fair value method. We have elected to account for these life insurance policies as investments using the fair value method.

We initially record our purchase of life insurance policies at the transaction price, which is the amount paid for the policy, inclusive of all fees and costs associated with the acquisition. The fair value of our investment in the portfolio of insurance policies is evaluated at the end of each reporting period. Changes in the fair value of the portfolio of life insurance policies are based on periodic evaluations and are recorded as changes in fair value of life insurance policies in our consolidated and combined statement of operations. The fair value is determined as the net present value of the life insurance portfolio’s future expected cash flows that incorporates current life expectancy estimates and discount rate assumptions.

Page 29

In addition to reporting our results of operations and financial condition based on the fair value of our life insurance policies as required by GAAP, management also makes calculations based on the weighted average expected internal rate of return of the policies. See “Non-GAAP Financial Measures” below.

Valuation of Insurance Policies

Unobservable inputs, as discussed below, are a critical component of our estimate for the fair value of our investments in life insurance policies. We currently use a probabilistic method of estimating and valuing the projected cash flows of our portfolio of life insurance policies, which we believe to be the preferred and most prevalent valuation method in the industry. In this regard, the most significant assumptions we make are the life expectancy estimates of the insureds and the discount rate applied to the projected cash flows to be derived from our portfolio.

In determining life expectancy estimates, we generally use actuarial medical reviews from independent medical underwriters. These medical underwriters summarize the health of the insured by reviewing historical and current medical records. The medical underwriters evaluate the health condition of the insured in order to produce an estimate of the insured’s mortality—a life expectancy report. In the case of a small face policy ($1 million face value or less), we may use one life expectancy report or estimate life expectancy based on a modified methodology which does not use actuarial medical reviews from independent medical underwriters. The life expectancy estimate represents a range of probabilities for the insured’s mortality against a group of cohorts with the same age, sex and smoking status. These mortality probabilities represent a mathematical curve known as a mortality curve, which is then used to generate a series of expected cash flows from the life insurance policy over the expected lifespan of the insured. A discount rate is used to calculate the net present value of the expected cash flows. The discount rate represents the internal rate of return we expect to earn on investments in a policy or in the portfolio as a whole at the stated fair value. The discount rate used to calculate fair value of our portfolio incorporates the guidance provided by ASC 820, Fair Value Measurements and Disclosures . Many of our current underwriting review processes, including our policy of obtaining actuarial medical reviews from independent medical underwriters as described above, are undertaken in satisfaction of obligations under our revolving credit facility. As a result, we may in the future modify our underwriting review processes if permitted under our borrowing arrangements.

The table below provides the discount rate used to estimate the fair value of the life insurance policies for the period ending:

June 30, 2014		December 31, 2013
11.56%		11.69%

The change in the discount rate incorporates current information about discount rates applied by other reporting companies owning portfolios of life insurance policies, discount rates observed in the life insurance secondary market, market interest rates, the credit exposure to the issuing insurance companies and our estimate of the risk premium a purchaser would require to receive the future cash flows derived from our portfolio of life insurance policies. The discount rate to arrive at the fair value of our portfolio assumes an orderly and arms-length transaction (i.e., a non-distressed transaction in which neither seller nor buyer is compelled to engage in the transaction).

We engaged a third party, Model Actuarial Pricing Systems (MAPS), to prepare a third-party valuation of our life settlement portfolio. MAPS owns and maintains the portfolio pricing software we use. MAPS processed policy data, future premium data, life expectancy estimate data, and other actuarial information we supply to calculate a net present value for our portfolio using the specified discount rate of 11.56%. MAPS independently calculated the net present value of our portfolio of 289 policies to be $267,895,692, which is the same fair value estimate we used on the balance sheet as of June 30, 2014, and furnished us with a letter documenting its calculation. A copy of such letter is filed as Exhibit 99.1 to this report.

JOBS Act

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or JOBS Act, was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933 for complying with new or revised accounting standards. This means that an “emerging growth company” can make an election to delay the adoption of certain accounting standards until those standards would apply to private companies. We have elected to delay such adoption of new or revised accounting standards and, as a result, we may not comply with new or revised accounting standards at the same time as other public reporting companies that are not “emerging growth companies.” This exemption will apply for a period of five years following our first sale of common equity securities under an effective registration statement or until we no longer qualify as an “emerging growth company” as defined under the JOBS Act, whichever is earlier.

Page 30

Deferred Income Taxes

FASB ASC 740, Income Taxes , requires us to recognize deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is established for any portion of deferred tax assets that is not considered more likely than not to be realized.

We have provided a valuation allowance against the deferred tax asset related to a note receivable because we believe that, when realized for tax purposes, it will result in a capital loss that will not be utilized because we have no expectation of generating a capital gain within the applicable carryforward period. Therefore, we do not believe that it is more likely than not that the deferred tax asset will be realized.

We have also provided a valuation allowance against the deferred tax asset related to a tax basis capital loss generated with respect to its settlement and subsequent disposal of our investment in Athena Structured Funds PLC (see “Notes to Consolidated Financial Statements” Note 10). As we have no expectation of generating capital gains within the applicable carry-forward period, we do not believe that it is more likely than not that the deferred asset will be realized.

A valuation allowance is required to be recognized to reduce deferred tax assets to an amount that is more likely than not to be realized. Realization of deferred tax assets depends upon having sufficient past or future taxable income in periods to which the deductible temporary differences are expected to be recovered or within any applicable carryback or carryforward periods. We believe that it is more likely than not that we will be able to realize all of our deferred tax assets other than that which is expected to result in a capital loss.

Deferred Financing and Issuance Costs

Financing costs incurred to obtain financing under the revolving credit facility have been capitalized and are amortized using the straight-line method over the term of the revolving credit facility. The Series I Secured note obligations are reported net of issuance costs, sales commissions and other direct expenses, which are amortized using the interest method over the term of each respective borrowing. The Renewable Secured Debentures are reported net of issuance costs, sales commissions and other direct expenses, which are amortized using the interest method over the term of each respective borrowing. The Series A preferred stock is reported net of issuance costs, sales commissions, including the fair value of warrants issued, and other direct expenses, which are amortized using the interest method as interest expense over the three-year redemption period.

Risk Relating to Forward-Looking Statements

Certain matters discussed in this section of this report, and elsewhere in this report, are forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, these forward-looking statements are subject to risks, uncertainties and assumptions about our operations and the investments we make, including, among other things, the following:

●	changes in the secondary market for life insurance;
●	our limited operating history;
●	the valuation of assets reflected on our financial statements;
●	the reliability of our life expectancy estimates;
●	the reliability of assumptions underlying our actuarial models;
●	our reliance of debt financing;
●	risks relating to the validity and enforceability of the life insurance policies we purchase;
●	our reliance on information provided and obtained by third parties;
●	federal and state regulatory matters;
●	additional expenses, not reflected in our operating history, related to being a public reporting company;
●	competition in the secondary life insurance market;
●	the relative illiquidity of life insurance policies;
●	life insurance company credit exposure;
●	economic outlook;
●	performance of our investments in life insurance policies;
●	financing requirements;
●	litigation risks; and
●	restrictive covenants contained in borrowing agreements.

Forward-looking statements can generally be identified by the use of words like “believes,” “could,” “possibly,” “probably,” “anticipates,” “estimates,” “projects,” “expects,” “may,” “will,” “should,” “seek,” “intend,” “plan,” “expect” or “consider,” or the negative of these expressions or other variations, or by discussions of strategy that involve risks and uncertainties. All forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual transactions, results, performance or achievements to be materially different from any future transactions, results, performance or achievements expressed or implied by such forward-looking statements.

Page 31

Principal Revenue and Expense Items

We earn revenues from three primary sources as described below.

●

Policy Benefits Realized . We recognize the difference between the death benefits and carrying values of the policy when an insured event has occurred and we determine that settlement and ultimate collection of the death benefits is realizable and reasonably assured. Revenue from a transaction must meet both criteria in order to be recognized. We generally collect the face value of the life insurance policy from the insurance company within 45 days of the insured’s mortality.

●

Change in Fair Value of Life Insurance Policies . We have elected to carry our investments in life insurance policies at fair value in accordance with ASC 325-30, Investments in Life Insurance Contracts . Accordingly, we value our investments in our portfolio of life insurance policies each reporting period in accordance with the fair value principles discussed herein, which includes the expected payment of premiums for future periods.

●	Sale of a Life Insurance Policy or a Portfolio of Life Insurance Policies . In an event of a sale of a policy, we recognize gain or loss as the difference between the sale price and the carrying value of the policy on the date of the receipt of payment on such sale.

Our main components of expense are summarized below.

●

Selling, General and Administrative Expenses . We recognize and record expenses incurred in the operations of the purchasing and servicing of life insurance policies. These expenses include professional fees, salaries, and sales and marketing expenditures.

●

Interest Expense . We recognize and record interest expenses associated with the costs of financing our life insurance portfolio for the current period. These expenses include interest paid to our senior lender under our revolving credit facility, as well as all interest paid on our debentures and other outstanding indebtedness such as our subsidiary secured notes and dividends on convertible, redeemable preferred stock. When we issue long-term indebtedness, we amortize the issuance costs associated with such indebtedness over the outstanding term of the financing, and classify it as interest expense.

Results of Operations — Three and Six Months Ended June 30, 2014 Compared to the Same Periods in 2013

The following is our analysis of the results of operations for the periods indicated below. This analysis should be read in conjunction with our consolidated financial statements and related notes.

Revenue . Revenue recognized from the receipt of policy benefits was $231,000 during both three and six months ended June 30, 2014. Revenue recognized from the receipt of policy benefits was $5,218,000 and $7,728,000 during the three and six months ended June 30, 2013, respectively. Revenue recognized from the change in fair value of our life insurance policies, net of premiums and carrying costs, was $5,253,000 and $10,770,000 for the three and six months ended June 30, 2014, respectively and $2,515,000 and $8,346,000 for the three and six months ended June 30, 2013, respectively. During the six-month period ended June 30, 2013, we purchased a higher volume of life insurance policies than we did during the same period in 2014. The change in fair value related to new policies acquired during the three and six month periods ended June 30, 2014 was $1,595,000 and $6,559,000 respectively, and $2,471,000 and $8,770,000 for those acquired during the three-month and six-month periods ended June 30, 2013, respectively. In each case, the increases in fair value were due to changes in the discount rates we use to calculate the net present value of cash flows expected from our portfolio of life insurance policies, change in fair value of policies acquired during the period, and aging of the policies. Decreases in fair value were due to changes in life expectancy estimates. The discount rate incorporates current information about market interest rates, the credit exposure to the insurance companies that issued the life insurance policies in our portfolio and our estimate of the risk premium an investor would require to receive the future cash flows from our portfolio of life insurance policies. The discount rate used to estimate the fair value of the life insurance policies we own was 11.56% as of June 30, 2014, compared to 11.84% as of June 30, 2013. The decrease in discount rate was due to changes in a variety of factors in our fair value methodology. The carrying value of policies acquired during each quarterly reporting period are adjusted to their current fair value using the fair value discount rate applied to the portfolio as of that reporting date.

Page 32

Expenses . Interest expense, including amortization of the deferred financing costs as well as preferred stock dividends, were $6,608,000 and $12,935,000 during the three and six months ended June 30, 2014, compared to $4,942,000 and $9,409,000 during the same periods of 2013, increases of $1,666,000 and $3,526,000, respectively. The increase was due the increased debt outstanding that went up from $210,157,000 at June 30, 2013 to $268,603,000 at June 30, 2014. Selling, general, and administrative expenses were $2,787,000 and $4,840,000 during the three and six months ended June 30, 2014, compared to $2,507,000 and $5,915,000 during the same periods of 2013, an increase of $280,000 and a decrease of $1,075,000, respectively. The decrease is mostly due to $825,000 in discretionary bonuses equal to the tax effect of the conversion from an LLC to a corporation, paid to the original LLC members in the first quarter of 2013. The payments under our incentive compensation plan were also higher in the first quarter of 2013 compared to those in the same period of 2014 due to higher volume of life insurance contracts purchased.

Income Tax Expense. For the three and six months ended June 30, 2014, we had a loss of $3,903,000 and $6,759,000 before income taxes and recorded income tax benefit of $1,317,000 and $2,272,000, respectively, or 33.7% and 33.6%, respectively. In the same periods of 2013, we had $3,559,000 and $4,192,000 income before income taxes and recognized an income tax expense of $1,802,000 and $2,368,000, respectively, or 50.6% and 56.5%, respectively. The primary differences between our effective tax rate and the statutory federal rate are the accrual of preferred stock dividend expense, state taxes, and other non-deductible expenses. Excluding the impact of the dividends and other permanent differences, the effective tax rate for the three and six months ended June 30, 2014 and 2013 would have been 43.8% and 40.5%, respectively.

The following table provides a reconciliation of our income tax expense at the statutory federal tax rate to our actual income tax expense:

	Three Months Ended					Six Months Ended					Three Months Ended				Six Months Ended
Six months ended:	June 30, 2014					June 30, 2014					June 30, 2013				June 30, 2013
Statutory federal income tax	$	(1,327,000	)	34.0	%	$	(2,298,000	)	34.0	%	$	1,210,000	34.0	%	$	1,425,000	34.0	%
State income taxes, net of federal benefit		(209,000	)	5.4	%		(352,000	)	5.2	%		271,000	7.6	%		356,000	8.5	%
Series A preferred stock dividends		218,000		(5.6	) %		434,000		(6.4	) %		214,000	6.0	%		430,000	10.2	%
Other permanent differences		1,000		(0.1	) %		(56,000	)	0.8	%		107,000	3.0	%		157,000	3.8	%
Total income tax expense	$	(1,317,000	)	33.7	%	$	(2,272,000	)	33.6	%	$	1,802,000	50.6	%	$	2,368,000	56.5	%

The most significant temporary differences between GAAP net income and taxable net income are the treatment of interest costs with respect to the acquisition of the life insurance policies and revenue recognition with respect to the mark-to-market of life insurance portfolio.

Liquidity and Capital Resources

We finance our business through a combination of policy benefit revenues, origination fees, equity offerings, debt offerings, and a credit facility. We have used our debt offerings and credit facility primarily for policy acquisition, policy servicing and portfolio related financing expenditures. We charge an intercompany origination fee in the amount of one to four percent of the face value of a life insurance policy’s benefit when we acquire the related life insurance policy. The origination fee we charge is included in the total purchase price we pay for a life insurance policy for purposes of our valuation and expected internal rate of return calculations, but is not netted against the purchase price we pay to a seller of an insurance policy. We generated cash flows of $343,000 and $1,309,000 from origination fees during the three and six months ended June 30, 2014, and $536,000 and $1,814,000 during the same periods in 2013. Profit from intra-company origination fees for life insurance policies retained by the Company are eliminated from our consolidated statements of operations. As such, the origination fees collected under our life insurance policy financing arrangements are reflected in our consolidated statements of cash flows as cash flows from financing activities as they are received form of borrowings used to finance the acquisition of life insurance policies. Our revolving bank line allows DLP II to borrow the funds necessary to pay origination fees to GWG Life. Our borrowing agreements allow us to use net proceeds of the Renewable Secured Debentures for policy acquisition, which includes origination fees. If the policy acquisition is not financed, no fees are included in the consolidated cash flows. See “Cash Flows” below for further information. We determine the purchase price of life insurance policies in accordance with ASC 325-30, Investments in Insurance Contracts , using the fair value method. Under the fair value method, the initial investment is recorded at the transaction price. Because the origination fees are paid from a wholly owned subsidiary to the parent company, these fees are not included in the transaction price as reflected in our consolidated financial statements. For further discussion on our accounting policies for life settlements, please refer to note 1 to our consolidated financial statements.

As of June 30, 2014, we had approximately $28.9 million in combined available cash and available borrowing base surplus capacity under our revolving credit facility for the purpose of purchasing additional life insurance policies, paying premiums on existing policies, paying portfolio servicing expenses, and paying principal and interest on our outstanding financing obligations.

Page 33

In September 2012, we concluded a Series A preferred stock offering, receiving an aggregate $24.6 million in subscriptions for our Series A preferred stock. These subscriptions consisted of $14.0 million in conversions of outstanding Series I Secured notes and $10.6 million of new investments. We have used the proceeds from the sale of our Series A preferred stock, together with the origination fees we received to purchase and finance life insurance policies to fund our operational expenditures.

In June 2011, we registered a $250.0 million debt offering of our Renewable Secured Debentures with the SEC, which registration became effective on January 31, 2012. Through June 30, 2014, the total amount of Renewable Secured Debentures sold, including renewals, is $198.0 million. As of June 30, 2014, we had approximately $161.0 million in principal amount of Renewable Secured Debentures outstanding.

Additionally, our wholly owned subsidiary GWG Life issued Series I Secured notes beginning in November 2009 on a private placement basis to accredited investors only. As of June 30, 2014, we had approximately $28.6 million in principal amount of Series I Secured notes outstanding. This offering was closed in November 2011.

The weighted-average interest rate of our outstanding Series I Secured notes as of June 30, 2014 and December 31, 2013 was 8.36% and 8.35%, respectively, and the weighted-average maturity at those dates was 2.06 and 2.49 years, respectively. The Series I Secured notes have renewal features. Since we first issued our Series I Secured notes, we have experienced $129,108,000 in maturities, of which as of June 30, 2014 $100,064,000 has renewed for an additional term. This has provided us with an aggregate renewal rate of approximately 77% for investments in our subsidiary secured notes. Future contractual maturities of Series I Secured notes payable at June 30, 2014 are:

Years Ending December 31,
Six months ending December 31, 2014	$	4,586,000
2015		10,718,000
2016		8,092,000
2017		4,428,000
2018		754,000
Thereafter		64,000
	$	28,642,000

The weighted-average interest rate of our outstanding Renewable Secured Debentures as of June 30, 2014 and December 31, 2013 was 7.51% and 7.53%, respectively, and the weighted average maturity at those dates was 3.60 and 3.69 years, respectively. Our Renewable Secured Debentures have renewal features. Since we first issued our Renewable Secured Debentures, we have experienced $37,069,000 in maturities, of which as of June 30, 2014 $23,048,000 has renewed for an additional term. This has provided us with an aggregate renewal rate of approximately 62% for investments in our Renewable Secured Debentures. Future contractual maturities of Renewable Secured Debentures at June 30, 2014 are:

Years Ending December 31,
Six months ending December 31, 2014	$	27,838,000
2015		47,254,000
2016		37,660,000
2017		16,949,000
2018		8,314,000
Thereafter		22,946,000
	$	160,961,000

The Renewable Secured Debentures and Series I Secured notes are secured by all our assets, and are subordinate to our revolving credit facility with Autobahn/DZ Bank. The Renewable Secured Debentures and Series I Secured notes are pari passu with respect to our assets pursuant to an inter-creditor agreement (see notes 7 and 8 to our consolidated financial statements).

We maintain a $100 million revolving credit facility with Autobahn/DZ Bank through GWG Life’s wholly owned subsidiary DLP II. As of June 30, 2014 and December 31, 2013 we had $79.0 million outstanding under the revolving credit facility and maintained an available borrowing base surplus of $5.8 and $3.9 million, respectively (see note 6 to our consolidated financial statements).

Page 34

We expect to meet our ongoing operational capital needs through a combination of policy benefit revenues, origination fees, and proceeds from financing transactions. We expect to meet our policy acquisition, servicing, and financing capital needs principally from the receipt of policy benefit revenues from our portfolio of life insurance policies, net proceeds from our offering of Renewable Secured Debentures, and from our revolving credit facility. Because we only receive origination fees when we purchase a policy, our receipt of those fees is contingent upon our consummation of policy purchases, which is, in turn, contingent upon our receipt of external funding. Despite recent adverse capital market conditions, including a prolonged credit crisis, we have demonstrated continued access to credit and financing markets. Furthermore, we expect to begin receiving insurance benefit payments on our portfolio of life insurance policies as the average age of the insureds increase and mortality events occur over time which we expect to begin more significantly in 2015 and steadily increasing until 2018. As a result of the foregoing, we estimate that our liquidity and capital resources are sufficient for our current and projected financial needs. Nevertheless, if we are unable to continue our offering of Renewable Secured Debentures for any reason (or if we become unsuccessful in selling debentures), and we are unable to obtain capital from other sources, we expect that our business would be materially and adversely affected. In addition, our business would be materially and adversely affected if we did not receive the policy benefits we forecast and if holders of our Renewable Secured Debentures or Series I Secured notes failed to renew with the frequency we have historically experienced. In such a case, we could be forced to sell our investments in life insurance policies to service or satisfy our debt-related obligations and continue to pay policy premiums.

Capital expenditures have historically not been material and we do not anticipate making material capital expenditures in 2013 or beyond.

Debt Financings Summary

We had the following outstanding debt balances as of June 30, 2014:

Issuer/Borrower	Principal Amount Outstanding		Weighted Average Interest Rate
GWG Holdings, Inc. - Renewable Secured Debentures	$	160,961,000		7.51	%
GWG Life Settlements, LLC -Series I Secured notes		28,642,000		8.36	%
GWG DLP Funding II, LLC - Revolving credit facility		79,000,000		6.19	%
Total	$	268,603,000		7.21	%

Our total credit facility and other indebtedness balance as of June 30, 2014 and December 31, 2013 was $268,603,000 and $243,635,000, respectively. At June 30, 2014, the total outstanding face amount under our Series I Secured notes outstanding was $28,642,000, less unamortized selling costs of $591,000, resulting in a carrying amount of $28,051,000. At December 31, 2013, the total outstanding face amount under our Series I Secured notes outstanding was $29,744,000, less unamortized selling costs of $469,000, resulting in a carrying amount of $29,275,000. At June 30, 2014, the total outstanding face amount of Renewable Secured Debentures was $160,961,000 plus $1,973,000 of subscriptions in process, less unamortized selling costs of $5,421,000, resulting in a carrying amount of $157,513,000. At December 31, 2013, the total outstanding face amount of Renewable Secured Debentures outstanding was $134,891,000 plus $1,902,000 of subscriptions in process, less unamortized selling costs of $5,147,000, resulting in a carrying amount of $131,646,000. At June 30, 2014, the fair value of our investments in life insurance policies of $267,896,000 plus our cash balance of $23,060,000 and our restricted cash balance of $2,810,000, totaled $293,766,000, representing an excess of portfolio assets over secured indebtedness of $25,163,000. At December 31, 2013, the fair value of our investments in life insurance policies of $234,673,000 plus our cash balance of $33,450,000 and our restricted cash balance of $5,833,000, totaled $273,956,000, representing an excess of portfolio assets over secured indebtedness of $30,321,000. The Renewable Secured Debentures and Series I Secured notes are secured by all our assets and are subordinate to our revolving credit facility with Autobahn/DZ Bank. The Renewable Secured Debentures and Series I Secured notes are pari passu with respect to shared collateral pursuant to an inter-creditor agreement.

Page 35

The following forward-looking table seeks to illustrate the impact of the sale of our portfolio of life insurance assets at various discount rates in order to satisfy our debt obligations as of June 30, 2014. In all cases, the sale of the life insurance assets owned by DLP II will be used first to satisfy all amounts owing under the revolving credit facility with Autobahn/ DZ Bank. The net sale proceeds remaining after satisfying all obligations under the revolving credit facility would be applied to Renewable Secured Debentures and Series I Secured notes on a pari passu basis.

Portfolio Discount Rate		10%		12%		13%		14%
Value of portfolio	$	289,810,000	$	262,199,000	$	249,964,000	$	238,638,000
Cash and cash equivalents		25,870,000		25,870,000		25,870,000		25,870,000
Total assets		315,680,000		288,069,000		275,834,000		264,508,000
Revolving credit facility Autobahn/DZ Bank		79,000,000		79,000,000		79,000,000		79,000,000
Net after revolving credit facility		236,680,000		209,069,000		196,834,000		185,508,000
Series I Secured notes and Renewable Secured Debentures		189,603,000		189,603,000		189,603,000		189,603,000
Net after Series I Secured notes and Renewable Secured Debentures		47,077,000		19,466,000		7,231,000		(4,095,000	)
Impairment to Series I Secured notes and Renewable Secured Debentures	No impairment		No impairment		No impairment		Impairment

The table illustrates that our ability to fully satisfy amounts owing under the Renewable Secured Debentures and Series I Secured notes would likely be impaired upon the sale of all our life insurance assets at a price equivalent to a discount rate of approximately 13.63% or higher. The discount rates used to calculate the fair value of our portfolio for mark-to-market accounting were 11.56% and 11.69% as of June 30, 2014 and December 31, 2013, respectively. The table does not include any allowance for transactional fees and expenses associated with a portfolio sale (which expenses and fees could be substantial), and is provided to demonstrate how various discount rates used to value our portfolio could affect our ability to satisfy amounts owing under our debt obligations, in light of our senior secured lender’s right to priority payments. You should read the above table in conjunction with the information contained in other sections of this report, including our discussion of discount rates included under the “—Critical Accounting Policies – Valuation of Insurance Policies” caption above. This discussion and analysis is based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. The forward-looking presentation above is subject to numerous risks and uncertainties. Our actual results could differ materially from those suggested or implied by the above table. Please see the caption “Risk Relating to Forward-Looking Statements” above.

On May 29, 2014 Holdings, together with GWG Life and DLPII, entered into an Amendment No. 1 to Amended and Restated Credit and Security Agreement with Autobahn and DZ Bank (as committed lender and Agent). The amendment was entered into for the purpose of extending the maturity date for borrowings under the agreement to December 31, 2016.

Cash Flows

The payment of premiums and servicing costs to maintain life insurance policies represents our most significant requirement for cash disbursement. When a policy is purchased, we are able to calculate the minimum premium payments required to maintain the policy in-force. Over time as the insured ages, premium payments will increase; however, the probability of actually needing to pay the premiums decreases since mortality becomes more likely. These scheduled premiums and associated probabilities are factored into our expected internal rate of return and cash-flow modeling described herein. Beyond premiums, we incur policy servicing costs, including annual trustee and tracking costs, and debt servicing costs, including principal and interest payments. Until we receive a stable amount of proceeds from the policy benefits, we intend to pay these costs from our credit facility, when permitted, and through the issuance of debt securities, including Renewable Secured Debentures.

Page 36

For the quarter end dates set forth below, the following table illustrates the total amount of face value of policy benefits owned, and the trailing 12 months of life insurance policy benefits collected and premiums paid on our portfolio. The trailing 12-month benefits/premium coverage ratio indicates the ratio of policy benefits received to premiums paid over the trailing 12-month period from our portfolio of life insurance policies.

Quarter End Date	Portfolio Face Amount		12-Month Trailing Benefits Collected		12-Month Trailing Premiums Paid		12-Month Trailing Benefits/Premium Coverage Ratio
March 31, 2012	$	482,455,000	$	4,203,000	$	14,977,000		28.06	%
June 30, 2012		489,255,000		8,703,000		15,412,000		56.47	%
September 30, 2012		515,661,000		7,833,000		15,837,000		49.46	%
December 31, 2012		572,245,000		7,350,000		16,597,000		44.28	%
March 31, 2013		639,755,000		11,350,000		18,044,000		62.90	%
June 30, 2013		650,655,000		13,450,000		19,182,000		70.11	%
September 30, 2013		705,069,000		18,450,000		20,279,000		90.98	%
December 31, 2013		740,648,000		16,600,000		21,733,000		76.38	%
March 31, 2014		771,940,000		12,600,000		21,930,000		57.46	%
June 30, 2014		784,652,000		6,300,000		22,598,000		27.88	%

We believe that the portfolio cash flow results set forth above represent our general investment thesis: that the life insurance policy benefits we receive will continue to increase over time in relation to the premiums we are required to pay on the remaining polices in the portfolio. Nevertheless, we expect that our portfolio cash flow results will remain inconsistent until such time we achieve our goal of acquiring a larger, more diversified portfolio of life insurance policies in order to obtain more normalized actuarial results. For example, we had expected to receive a greater amount of insurance benefits for the periods ended December 31, 2013 and June 30, 2014 than we actually experienced. As our receipt of life insurance policy benefits increase, we expect to begin servicing and paying down our outstanding indebtedness, or alternatively purchasing additional life insurance policies, from these cash flows. As indicated above under “Liquidity and Capital Resources,” we presently expect that by 2015, the cash inflows from the receipt of policy benefits will exceed the premium obligations on the remaining life insurance policies held within the portfolio as of December 31, 2013. See “Business—Portfolio Management.”

The amount of payments for anticipated premiums and servicing costs that we will be required to make over the next five years to maintain our current portfolio, assuming no mortalities, is set forth in the table below.

Year	Premiums and Servicing
Six months ending December 31, 2014	$	12,560,000
2015		27,040,000
2016		29,749,000
2017		33,194,000
2018		36,113,000
Total	$	138,656,000

The life insurance policies owned by DLP II are subject to a collateral arrangement with the agent to our revolving credit lender, as described in note 6 to the consolidated financial statements. Under this arrangement, collection and escrow accounts are used to fund purchases and premiums of the insurance policies and to pay interest and other charges under our revolving credit facility. The lender and its agent must authorize all disbursements from these accounts, including any distributions to GWG Life or Holdings. Distributions are limited to an amount that would result in the borrowers (DLP II, GWG Life, and Holdings) realizing an annualized rate of return on the equity funded amount for such assets of not more than 18%, as determined by the agent. After such amount is reached, the credit agreement requires that excess funds be used to fund repayments or a reserve account in a certain amount before any additional distributions may be made. In the future, these arrangements may restrict the cash flows available for payment of principal and interest on our debt obligations.

Inflation

Changes in inflation do not necessarily correlate with changes in interest rates. We presently do not foresee any material impact of inflation on our results of operations in the periods presented in our consolidated financial statements.

Page 37

Off-Balance Sheet Arrangements

Operating Lease - We entered into an office lease with U.S. Bank National Association as the landlord. The lease was effective April 22, 2012 with a term through August 31, 2015. The lease is for 11,695 square feet of office space located at 220 South Sixth Street, Minneapolis, Minnesota. We are obligated to pay base rent plus common area maintenance and a share of the building operating costs. Minimum lease payments under the lease are as follows:

Nine months ending December 31, 2014	$	52,000
2015	$	70,000
Total	$	122,000

Credit Risk

We review the credit risk associated with our portfolio of life insurance policies when estimating its fair value. In evaluating the policies’ credit risk we consider insurance company solvency, credit risk indicators, economic conditions, ongoing credit evaluations, and company positions. We attempt to manage our credit risk related to life insurance policies typically by purchasing policies issued only from companies with an investment grade credit rating by either Standard & Poor’s, Moody’s, or A.M. Best Company. As of June 30, 2014, 99.08% of our life insurance policies, by face value benefits, were issued by companies that maintained an investment grade rating (BBB or better) by Standard & Poor’s.

Interest Rate Risk

Our credit facility is floating-rate financing. In addition, our ability to offer interest rates that attract capital (including in the offer and sale of Renewable Secured Debentures) is generally impacted by prevailing interest rates. Furthermore, while our other indebtedness provides us with fixed-rate financing, our debt coverage ratio is calculated in relation to our total cost of financing. Therefore, fluctuations in interest rates impact our business by increasing our borrowing costs, and reducing availability under our debt financing arrangements. Furthermore, we calculate our portfolio earnings based upon the spread generated between the return on our life insurance portfolio and the cost of our financing. As a result, increases in interest rates will reduce the earnings we expect to achieve from our investments in life insurance policies.

Non-GAAP Financial Measures

We use non-GAAP financial measures when evaluating our financial results, for planning and forecasting purposes, and for maintaining compliance with covenants contained in our borrowing agreements. Non-GAAP financial measures disclosed by management are provided as additional information to investors in order to provide them with an alternative method for assessing our financial condition and operating results. These non-GAAP financial measures are not in accordance with GAAP and may be different from non-GAAP measures used by other companies, including other companies within our industry. This presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for comparable amounts prepared in accordance with GAAP. See the notes to our consolidated financial statements and our audited financial statements contained herein.

We have elected to carry our investments in life insurance policies at fair value in accordance with ASC 325-30, Investments in Life Insurance Contracts . Accordingly, we value our investments in life insurance policies at the conclusion of each reporting period in accordance with GAAP fair value accounting principles. In addition to GAAP, we are required to report non-GAAP financial measures to Autobahn/DZ Bank under certain financial covenants made to that lender under our revolving credit facility. As indicated above, we also use non-GAAP financial reporting to manage and evaluate the financial performance of our business.

GAAP-based fair value requires us to mark-to-market our investments in life insurance policies, which by its nature, is based upon Level 3 measurements that are unobservable. As a result, this accounting treatment imports financial market volatility and subjective inputs into our financial reporting. We believe this type of accounting reporting is at odds with one of the key attractions for purchasing and owning a portfolio life insurance policies: the non-correlated nature of the returns to be derived from such policies. Therefore, in contrast to a GAAP-based fair valuation, we seek to measure the accrual of the actuarial gain occurring within the portfolio of life insurance policies at their expected internal rate of return based on statistical mortality probabilities for the insureds (using primarily the insured’s age, sex and smoking status). The expected internal rate of return tracks actuarial gain occurring within the policies according to a mortality table as the insureds’ age increases. By comparing the actuarial gain accruing within our portfolio of life insurance policies against our costs during the same period, we can estimate, manage and evaluate the overall financial profitability of our business without regard to mark-to-market volatility. We use this information to balance our life insurance policy purchasing and manage our capital structure, including the issuance of debt and utilization of our other sources of capital, and to monitor our compliance with borrowing covenants. We believe that these non-GAAP financial measures provide information that is useful for investors to understand period-over-period operating results separate and apart from fair value items that may, or could, have a disproportionately positive or negative impact on results in any particular period.

Page 38

Our credit facility requires us to maintain a “positive net income” and “tangible net worth” each of which are calculated on an adjusted non-GAAP basis on the method described above, without regard to GAAP-based fair value measures. In addition, our revolving credit facility requires us to maintain an “excess spread,” which is the difference between (i) the weighted average of our expected internal rate of return of our portfolio of life insurance policies and (ii) the weighted average of our credit facility’s interest rate. These calculations are made using non-GAAP measures in the method described below, without regard to GAAP-based fair value measures.

In addition, our Renewable Secured Debentures and Series I Secured notes require us to maintain a “debt coverage ratio” designed to ensure that the expected cash flows from our portfolio of life insurance policies is able to adequately service our total outstanding indebtedness. In addition, our Renewable Secured Debentures requires us to maintain a “subordination ratio” which limits the total amount of indebtedness that can be issued senior in rank to the Renewable Secured Debentures and Series I Secured notes. These ratios are calculated using non-GAAP measures in the method described below, without regard to GAAP-based fair value measures.

Adjusted Non-GAAP Net Income . Our credit facility requires us to maintain a positive net income calculated on an adjusted non-GAAP basis. We calculate the adjusted net income by recognizing the actuarial gain accruing within our life insurance policies at the expected internal rate of return of the policies we own without regard to fair value. We net this actuarial gain against our costs during the same period to calculate our net income on a non-GAAP basis.

	Three Months Ended June 30,						Six Months Ended June 30,
	2014			2013			2014			2013
GAAP net income	$	(2,587,000	)	$	1,757,000		$	(4,488,000	)	$	1,824,000
Unrealized fair value gain (1)		(10,852,000	)		(7,449,000	)		(22,211,000	)		(18,944,000	)
Adjusted cost basis increase (2)		10,777,000			8,641,000			22,174,000			18,897,000
Accrual of unrealized actuarial gain (3)		7,822,000			5,165,000			15,127,000			10,198,000
Total adjusted non-GAAP income (4)	$	5,160,000		$	8,114,000		$	10,602,000		$	11,975,000

(1)	Reversal of unrealized fair value gain of life insurance policies for current period.
(2)	Adjusted cost basis is increased to include those acquisition and servicing expenses which are not capitalized by GAAP.
(3)	Accrual of actuarial gain at expected internal rate of return based on investment cost basis for the period.
(4)	We must maintain an annual positive consolidated net income, calculated on a non-GAAP basis, to maintain compliance with our revolving credit facility with DZ Bank/Autobahn.

Adjusted Non-GAAP Tangible Net Worth . Our revolving credit facility requires us to maintain a tangible net worth in excess of $15 million calculated on an adjusted non-GAAP basis. We calculate the adjusted tangible net worth by recognizing the actuarial gain accruing within our life insurance policies at the expected internal rate of return of the policies we own without regard to fair value. We net this actuarial gain against our costs during the same period to calculate our tangible net worth on a non-GAAP basis.

	As of June 30, 2014			As of December 31, 2013
GAAP net worth (1)	$	15,176,000		$	19,231,000
Less intangible assets (2)		(7,481,000	)		(6,068,000	)
GAAP tangible net worth		7,695,000			13,163,000
Unrealized fair value gain (3)		(136,955,000	)		(114,744,000	)
Adjusted cost basis increase (4)		128,291,000			106,201,000
Accrual of unrealized actuarial gain (5)		64,794,000			49,666,000
Total adjusted non-GAAP tangible net worth (6)	$	63,825,000		$	54,286,000

(1)	Includes termination of redeemable member’s interest prior to corporate conversion and preferred stock classified as temporary equity.
(2)	Unamortized portion of deferred financing costs and pre-paid insurance.
(3)	Reversal of cumulative unrealized fair value gain or loss of life insurance policies.
(4)	Adjusted cost basis is increased by acquisition and servicing expenses which are not capitalized under GAAP.
(5)	Accrual of cumulative actuarial gain at expected internal rate of return based on investment cost basis.
(6)	We must maintain a total adjusted non-GAAP tangible net worth of $15 million to maintain compliance with our revolving credit facility with DZ Bank/Autobahn.

Page 39

Excess Spread . Our revolving credit facility requires us to maintain a 2.00% “excess spread” between our weighted-average expected internal rate of return of our portfolio of life insurance policies and the credit facility’s interest rate. A presentation of our excess spread and our total excess spread is set forth below. Management uses the “total excess spread” to gauge expected profitability of our investments, and uses the “excess spread” to monitor compliance with our borrowing.

	As of March 31, 2014			As of December 31, 2013
Weighted-average expected IRR (1)		12.04	%		12.21	%
Weighted-average revolving credit facility interest rate (2)		6.19	%		6.19	%
Excess spread (3)		5.85	%		6.02	%
Total weighted-average interest rate on indebtedness for borrowed money (4)		7.21	%		7.20	%
Total excess spread		4.83	%		5.01	%

(1)

This represents the weighted-average expected internal rate of return of the life insurance policies as of the measurement date based upon our investment cost basis of the insurance policies and the expected cash flows from the life insurance portfolio. Our investment cost basis is calculated as our cash investment in the life insurance policies, without regard to GAAP-based fair value measurements, and is set forth below:

Investment Cost Basis	As of June 30, 2014			As of December 31, 2013
GAAP fair value	$	267,896,000		$	234,673,000
Unrealized fair value gain (A)		(136,955,000	)		(114,744,000	)
Adjusted cost basis increase (B)		128,291,000			106,201,000
Investment cost basis (C)	$	259,232,000		$	226,130,000

	(A)	This represents the reversal of cumulative unrealized GAAP fair value gain of life insurance policies.
	(B)	Adjusted cost basis is increased to include those acquisition and servicing expenses that are not capitalized by GAAP.
	(C)	This is the full cash investment cost basis in life insurance policies from which our expected internal rate of return is calculated.
(2)	This is the weighted-average revolving credit relating to our revolving credit facility interest rate as of the measurement date.
(3)	We must maintain an excess spread of 2.00% relating to our revolving credit facility to maintain compliance under such facility.
(4)	Represents the weighted-average interest rate paid on all outstanding indebtedness as of the measurement date, determined as follows:

Outstanding Indebtedness	As of June 30, 2014		As of December 31, 2013
Revolving credit facility	$	79,000,000	$	79,000,000
Series I Secured notes		28,642,000		29,744,000
Renewable Secured Debentures		160,961,000		134,891,000
Total	$	268,603,000	$	243,635,000

Page 40

Interest Rates on Indebtedness
Revolving credit facility	6.19	%	6.19	%
Series I Secured notes	8.36	%	8.35	%
Renewable Secured Debentures	7.51	%	7.53	%
Weighted-average interest rates on indebtedness	7.21	%	7.20	%

Debt Coverage Ratio and Subordination Ratio. Our Renewable Secured Debentures and Series I Secured notes require us to maintain a “debt coverage ratio” of less than 90%. The “debt coverage ratio” is calculated by dividing the sum of our total indebtedness by the sum of our cash and cash equivalents and the net present value of the life insurance portfolio. The “subordination ratio” for our Renewable Secured Debentures is calculated by dividing the total indebtedness that is senior to Renewable Secured Debentures and Series I Secured notes by the sum of the company’s cash and cash equivalents and the net present value of the life insurance portfolio. The “subordination ratio” must be less than 50%. For purposes of both ratio calculations, the net present value of the life insurance portfolio is calculated using a discount rate equal to the weighted average interest rate of all indebtedness.

	As of June 30, 2014			As of December 31, 2013
Life insurance portfolio policy benefits	$	784,652,000		$	740,648,000
Discount rate of future cash flows		7.21	%		7.20	%
Net present value of Life insurance portfolio policy benefits	$	336,987,000		$	302,761,000
Cash and cash equivalents		25,870,000			39,283,000
Total Coverage		362,857,000			332,044,000

Revolving credit facility		79,000,000			79,000,000
Series I Secured notes		28,642,000			29,744,000
Renewable Secured Debentures		160,961,000			134,891,000
Total Indebtedness	$	268,603,000		$	243,635,000

Debt Coverage Ratio		74.02	%		71.23	%
Subordination Ratio		21.77	%		23.10	%

As of June 30, 2014, we were in compliance with both the debt coverage ratio and the subordination ratio as required under our related financing agreements for Renewable Secured Debentures and Series I Secured notes.

Our Portfolio

Our portfolio of life insurance policies, owned by our subsidiaries as of June 30, 2014, is summarized below:

Life Insurance Portfolio Summary

Total portfolio face value of policy benefits		$	784,652,000
Average face value per policy		$	2,715,000
Average face value per insured life		$	3,006,000
Average age of insured (yrs.) *			82.5
Average life expectancy estimate (yrs.) *			6.85
Total number of policies			289
Number of unique lives			261
Demographics	67% Males; 33% Females
Number of smokers	3 insureds are smokers
Largest policy as % of total portfolio			1.27	%
Average policy as % of total portfolio			0.35	%
Average Annual Premium as % of face value			3.21	%

* Averages presented in the table are weighted averages.

Page 41

Our portfolio of life insurance policies, owned by our subsidiaries as of June 30, 2014, organized by the insured’s current age and the associated policy benefits, is summarized below:

Distribution of Policy Benefits by Current Age of Insured

Min Age	Max Age	Policy Benefits		Weighted Average Life Expectancy (yrs.)	Distribution
65	69	$	9,156,000	7.84		1.17	%
70	74		48,617,000	9.16		6.20	%
75	79		169,198,000	8.46		21.56	%
80	84		300,764,000	7.28		38.33	%
85	89		226,596,000	4.96		28.88	%
90	95		30,321,000	3.70		3.86	%
Total		$	784,652,000	6.85		100.00	%

Our portfolio of life insurance policies, owned by our subsidiaries as of June 30, 2014, organized by the insured’s current age and number of policies owned, is summarized below:

Distribution of Policies by Current Age of Insured

Min Age	Max Age	Policies		Weighted Average Life Expectancy (yrs.)	Distribution
65	69		8	7.84		2.77	%
70	74		20	9.16		6.92	%
75	79		56	8.46		19.38	%
80	84		105	7.28		36.33	%
85	89		87	4.96		30.10	%
90	95		13	3.70		4.50	%
Total			289	6.85		100.00	%

Our portfolio of life insurance policies, owned by our subsidiaries as of June 30, 2014, organized by the insured’s estimated life expectancy estimates and associated policy benefits, is summarized below:

Distribution of Policy Benefits by Current Life Expectancies of Insured

Min LE (Months)	Max LE (Months)	Policy Benefits		Distribution
144	167	$	9,000,000		1.15	%
120	143		99,656,000		12.70	%
96	119		143,774,000		18.32	%
72	95		210,583,000		26.84	%
48	71		219,773,000		28.01	%
16	47		101,866,000		12.98	%
Total		$	784,652,000		100.00	%

We track concentrations of pre-existing medical conditions among insured individuals within our portfolio based on information contained in life expectancy reports. We track these medical conditions with ten primary disease categories: (1) cardiovascular, (2) cerebrovascular, (3) dementia, (4) cancer, (5) diabetes, (6) respiratory disease, (7) neurological disorders, (8) other, no disease, or multiple. Our primary disease categories are summary generalizations based on the ICD-9 codes we track on each insured individuals within our portfolio. ICD-9 codes, published by the World Health Organization, are used worldwide for medical diagnoses and treatment systems, as well as morbidity and mortality statistics. Currently, cardiovascular is the only primary disease category within our portfolio that represents a concentration over 10%.

Page 42

Our portfolio of life insurance policies, owned by our subsidiaries as of June 30, 2014, organized by the primary disease categories of the insured and associated policy benefits, is summarized below:

Distribution of Policy Benefits by Primary Disease Category

Primary Disease Category	Policy Benefits		Distribution
Cancer	$	57,450,000		7.32	%
Cardiovascular		141,876,000		18.08	%
Cerebrovascular		21,960,000		2.80	%
Dementia		62,699,000		7.99	%
Diabetes		63,617,000		8.11	%
Multiple		196,059,000		24.99	%
Neurological Disorders		15,840,000		2.02	%
No Disease		94,468,000		12.04	%
Other		89,483,000		11.40	%
Respiratory Diseases		41,200,000		5.25	%
Total Policy Benefits	$	784,652,000		100.00	%

The primary disease category represents a general category of impairment. Within the primary disease category, there are a multitude of sub-categorizations defined more specifically by ICD-9 codes. For example, a primary disease category of cardiovascular includes subcategorizations such as atrial fibrillation, heart valve replacement, coronary atherosclerosis, etc. In addition, individuals may have more than one ICD-9 code describing multiple medical conditions within one or more primary disease categories. Where an individual’s ICD-9 codes indicate medical conditions in more than one primary disease categories, we categorize the individual as having multiple primary disease categories. We expect to continue to develop and refine our identification and tracking on the insured individuals medical conditions as we manage our portfolio of life insurance policies.

Portfolio Credit Risk Management

The life insurance policies that we acquire represent obligations of third-party life insurance companies to pay the benefits under the relevant policy. Because we finance life insurance policies, we rely on the payments from the face value of policy benefits from life insurance companies for revenue collections. We rely on the face value of the life insurance policy benefit at maturity as the exclusive form of payment.

The possible insolvency or loss by a life insurance company is a significant risk to our business. To manage this risk, we seek to purchase policies that are issued by insurance companies with investment-grade ratings from either A.M. Best, Moody’s or Standard & Poor’s. To further mitigate risk, we seek to limit the face value of policy benefits issued by any one life insurance company within the total portfolio to 20%. State guaranty funds generally guaranty policy benefits up to $200,000. In addition, to assure diversity and stability in our portfolio, we regularly review the various metrics of our portfolio relating to credit risk. We track industry rating agency reports and industry journals and articles in order to gain insight into possible financial problems of life insurance companies. Recently, some of the credit ratings on insurance companies were downgraded and we will no longer consider purchasing policies issued by these insurance companies. Finally, we will only purchase those life insurance policies that meet the underwriting standards established in the indenture governing our Renewable Secured Debentures.

Page 43

As of June 30, 2014, 99.08% of insurance companies in our portfolio hold an investment-grade rating by Standard & Poor’s (BBB- or better), and the face value of policy benefits issued by one life insurance company with in the portfolio was 15.72%. Of the 44 insurance companies that insure the policies we own, ten companies insure approximately 72.66% of total face value of insurance benefits and the remaining 34 insurance companies insure the remaining approximately 27.34% of total face value of insurance benefits. The concentration risk of our ten largest insurance company holdings as of June 30, 2014 is set forth in the table below.

Rank	Policy Benefits		Percentage of Policy Benefit Amt.		Insurance Company	Ins. Co. S&P Rating
1	$	123,380,000		15.72%	AXA Equitable Life Insurance Company	A+
2	$	85,920,000		10.95%	John Hancock Life Insurance Company (U.S.A)	AA-
3	$	73,920,000		9.42%	Transamerica Life Insurance Company	AA-
4	$	58,769,000		7.49%	Jefferson-Pilot Life Insurance Company	AA-
5	$	56,215,000		7.16%	ING Life Insurance and Annuity Company	A-
6	$	43,550,000		5.55%	American General Life Insurance Company	A+
7	$	42,735,000		5.45%	Massachusetts Mutual Life Insurance Company	AA+
8	$	30,500,000		3.89%	Pacific Life Insurance Company	A+
9	$	28,450,000		3.63%	West Coast Life Insurance Company	AA-
10	$	26,661,000		3.40%	Metropolitan Life Insurance Company	AA-

Life Insurance Portfolio Detail

(as of June 30, 2014)

	Face Amount		Gender		Age (ALB)		LE (mo.)		Insurance Company	S&P Rating
1	$	4,000,000		M		93		38.1	MetLife Investors USA Insurance Company	AA-
2	$	1,100,000		M		93		32.4	ING Life Insurance and Annuity Company	A-
3	$	1,770,726		F		93		36.4	Aviva Life Insurance Company	A-
4	$	3,200,000		M		93		63.8	West Coast Life Insurance Company	AA-
5	$	1,000,000		F		92		42.6	Transamerica Life Insurance Company	AA-
6	$	250,000		M		91		25.5	Transamerica Life Insurance Company	AA-
7	$	2,500,000		M		90		27.2	Columbus Life Insurance Company	AA
8	$	3,000,000		M		90		56.4	West Coast Life Insurance Company	AA-
9	$	500,000		M		90		22.9	John Hancock Life Insurance Company (U.S.A)	AA-
10	$	5,000,000		F		90		60.9	American General Life Insurance Company	A +
11	$	2,000,000		F		90		22.0	Pruco Life Insurance Company	AA-
12	$	5,000,000		F		90		41.2	John Hancock Life Insurance Company (U.S.A)	AA-
13	$	1,000,000		F		90		38.4	Protective Life Insurance Company	AA-
14	$	1,682,773		F		89		59.4	Hartford Life and Annuity Insurance Company	BBB+
15	$	5,000,000		M		89		39.6	John Hancock Life Insurance Company (U.S.A)	AA-
16	$	3,100,000		F		89		42.0	Lincoln Benefit Life Company	BBB+
17	$	1,500,000		F		89		74.2	Jefferson-Pilot Life Insurance Company	AA-
18	$	1,000,000		M		89		34.9	State Farm Life Insurance Company	AA-
19	$	3,000,000		F		89		41.6	Jefferson-Pilot Life Insurance Company	AA-
20	$	500,000		F		89		34.1	Genworth Life Insurance Company	A-
21	$	1,000,000		F		89		34.1	Genworth Life Insurance Company	A-
22	$	1,000,000		F		89		34.1	Genworth Life Insurance Company	A-
23	$	500,000		F		89		34.1	Genworth Life Insurance Company	A-
24	$	1,000,000		M		89		13.9	ING Life Insurance and Annuity Company	A-
25	$	600,000		F		89		29.2	Columbus Life Insurance Company	AA
26	$	1,000,000		F		88		59.4	United of Omaha Life Insurance Company	A+
27	$	3,500,000		F		88		64.9	John Hancock Life Insurance Company (U.S.A)	AA-
28	$	1,750,000		M		88		29.6	Transamerica Life Insurance Company	AA-
29	$	2,500,000		F		88		15.8	AXA Equitable Life Insurance Company	A+

Page 44

		Face Amount	Gender	Age (ALB)	LE (mo.)	Insurance Company	S&P Rating
30	$	2,500,000	F	88	15.8	AXA Equitable Life Insurance Company	A+
31	$	5,000,000	F	88	48.5	ING Life Insurance and Annuity Company	A-
32	$	5,000,000	F	88	25.8	Lincoln National Life Insurance Company	AA-
33	$	715,000	F	88	68.9	Jefferson-Pilot Life Insurance Company	AA-
34	$	1,203,520	M	88	52.1	Columbus Life Insurance Company	AA
35	$	1,350,000	F	88	44.0	Jefferson-Pilot Life Insurance Company	AA-
36	$	2,000,000	F	88	37.5	American General Life Insurance Company	A+
37	$	3,500,000	F	88	50.0	Lincoln National Life Insurance Company	AA-
38	$	5,000,000	F	87	56.0	Massachusetts Mutual Life Insurance Company	AA+
39	$	2,500,000	F	87	56.6	American General Life Insurance Company	A+
40	$	2,500,000	M	87	47.6	Pacific Life Insurance Company	A+
41	$	4,000,000	F	87	81.8	Transamerica Life Insurance Company	AA-
42	$	5,000,000	M	87	62.3	AXA Equitable Life Insurance Company	A+
43	$	1,500,000	M	87	48.9	John Hancock Life Insurance Company (U.S.A)	AA-
44	$	1,500,000	M	87	48.9	John Hancock Life Insurance Company (U.S.A)	AA-
45	$	1,000,000	F	87	75.1	Transamerica Life Insurance Company	AA-
46	$	250,000	F	87	75.1	Transamerica Life Insurance Company	AA-
47	$	1,000,000	M	87	63.8	AXA Equitable Life Insurance Company	A+
48	$	500,000	M	87	70.5	Lincoln National Life Insurance Company	AA-
49	$	4,785,380	F	87	50.5	John Hancock Life Insurance Company (U.S.A)	AA-
50	$	8,985,000	M	87	40.1	Massachusetts Mutual Life Insurance Company	AA+
51	$	1,803,455	F	87	58.0	Metropolitan Life Insurance Company	AA-
52	$	1,529,270	F	87	58.0	Metropolitan Life Insurance Company	AA-
53	$	802,082	M	87	80.0	Lincoln National Life Insurance Company	AA-
54	$	5,000,000	M	87	60.9	John Hancock Life Insurance Company (U.S.A)	AA-
55	$	2,225,000	F	87	94.1	Transamerica Life Insurance Company	AA-
56	$	3,000,000	F	87	91.3	Massachusetts Mutual Life Insurance Company	AA+
57	$	1,500,000	M	87	54.7	Union Central Life Insurance Company	A+
58	$	3,000,000	M	87	52.9	Jefferson-Pilot Life Insurance Company	AA-
59	$	2,000,000	M	87	48.1	John Hancock Life Insurance Company (U.S.A)	AA-
60	$	3,000,000	M	87	41.7	American General Life Insurance Company	A+
61	$	500,000	F	86	77.7	Sun Life Assurance Company of Canada (U.S.)	BBB
62	$	5,000,000	F	86	43.2	Transamerica Life Insurance Company	AA-
63	$	3,000,000	M	86	61.7	Transamerica Life Insurance Company	AA-
64	$	1,200,000	M	86	69.2	Transamerica Life Insurance Company	AA-
65	$	250,000	M	86	81.4	Metropolitan Life Insurance Company	AA-
66	$	6,000,000	F	86	65.3	Sun Life Assurance Company of Canada (U.S.)	BBB
67	$	3,000,000	M	86	93.5	AXA Equitable Life Insurance Company	A+
68	$	5,570,000	F	86	56.5	ING Life Insurance and Annuity Company	A-
69	$	5,570,000	F	86	56.5	ING Life Insurance and Annuity Company	A-
70	$	1,000,000	F	86	44.1	New York Life Insurance Company	AA+
71	$	5,000,000	F	86	39.8	Penn Mutual Life Insurance Company	A+
72	$	10,000,000	F	86	81.5	West Coast Life Insurance Company	AA-

Page 45

Face Amount

Gender

Age

(ALB)

(mo.)

Insurance Company

S&P Rating

73	$	2,500,000	M	86	56.7	Transamerica Life Insurance Company	AA-
74	$	1,000,000	F	86	60.4	West Coast Life Insurance Company	AA-
75	$	2,000,000	F	86	60.4	West Coast Life Insurance Company	AA-
76	$	800,000	M	86	64.5	National Western Life Insurance Company	A
77	$	200,000	M	86	57.2	Lincoln Benefit Life Company	BBB+
78	$	4,445,467	M	86	67.6	Penn Mutual Life Insurance Company	A+
79	$	7,500,000	M	86	59.6	Jefferson-Pilot Life Insurance Company	AA-
80	$	3,600,000	F	86	67.0	AXA Equitable Life Insurance Company	A+
81	$	5,000,000	M	86	90.7	Lincoln National Life Insurance Company	AA-
82	$	1,000,000	F	86	35.6	John Hancock Life Insurance Company (U.S.A)	AA-
83	$	4,513,823	F	86	31.2	Aviva Life Insurance Company	A-
84	$	2,000,000	F	86	84.5	U.S. Financial Life Insurance Company	A+
85	$	1,000,000	M	85	69.9	John Hancock Life Insurance Company (U.S.A)	AA-
86	$	2,000,000	M	85	69.9	John Hancock Life Insurance Company (U.S.A)	AA-
87	$	5,000,000	M	85	57.6	Jefferson-Pilot Life Insurance Company	AA-
88	$	1,365,000	F	85	94.6	Transamerica Life Insurance Company	AA-
89	$	1,000,000	F	85	94.0	ING Life Insurance and Annuity Company	A-
90	$	1,000,000	M	85	48.5	Massachusetts Mutual Life Insurance Company	AA+
91	$	2,000,000	M	85	94.1	Transamerica Life Insurance Company	AA-
92	$	8,500,000	M	85	90.5	Massachusetts Mutual Life Insurance Company	AA+
93	$	1,000,000	M	85	33.3	Transamerica Life Insurance Company	AA-
94	$	500,000	M	85	91.4	Metropolitan Life Insurance Company	AA-
95	$	2,000,000	M	85	70.9	Jefferson-Pilot Life Insurance Company	AA-
96	$	500,000	F	85	64.8	Beneficial Life Insurance Company	N/A
97	$	1,800,000	M	85	60.7	John Hancock Variable Life Insurance Company	AA-
98	$	2,000,000	M	85	108.5	ING Life Insurance and Annuity Company	A-
99	$	2,000,000	M	85	108.5	ING Life Insurance and Annuity Company	A-
100	$	2,000,000	M	85	108.5	ING Life Insurance and Annuity Company	A-
101	$	1,500,000	M	84	58.0	Transamerica Life Insurance Company	AA-
102	$	3,750,000	M	84	85.1	AXA Equitable Life Insurance Company	A+
103	$	1,000,000	M	84	69.0	John Hancock Life Insurance Company (U.S.A)	AA-
104	$	2,000,000	F	84	94.7	AXA Equitable Life Insurance Company	A+
105	$	3,000,000	F	84	93.3	Sun Life Assurance Company of Canada (U.S.)	BBB
106	$	829,022	F	84	33.3	Hartford Life and Annuity Insurance Company	BBB+
107	$	1,500,000	M	84	88.9	AXA Equitable Life Insurance Company	A+
108	$	2,328,547	M	84	53.1	Metropolitan Life Insurance Company	AA-
109	$	2,000,000	M	84	53.1	Metropolitan Life Insurance Company	AA-
110	$	5,000,000	M	84	98.8	ING Life Insurance and Annuity Company	A-
111	$	1,500,000	M	84	58.0	ING Life Insurance and Annuity Company	A-
112	$	1,500,000	M	84	58.0	ING Life Insurance and Annuity Company	A-
113	$	3,000,000	F	84	80.6	Transamerica Life Insurance Company	AA-
114	$	5,000,000	M	84	82.5	ING Life Insurance and Annuity Company	A-
115	$	1,000,000	M	84	56.2	John Hancock Life Insurance Company (U.S.A)	AA-

Page 46

Face Amount

Gender

Age

(ALB)

(mo.)

Insurance Company

S&P Rating

116	$	4,000,000	F	84	58.5	ING Life Insurance and Annuity Company	A-
117	$	5,000,000	F	84	102.4	American General Life Insurance Company	A+
118	$	2,000,000	M	84	73.7	AXA Equitable Life Insurance Company	A+
119	$	1,750,000	M	84	73.7	AXA Equitable Life Insurance Company	A+
120	$	2,000,000	M	84	43.2	Transamerica Life Insurance Company	AA-
121	$	1,425,000	M	84	92.1	John Hancock Life Insurance Company (U.S.A)	AA-
122	$	5,000,000	F	83	106.8	AXA Equitable Life Insurance Company	A+
123	$	1,000,000	F	83	93.3	John Hancock Life Insurance Company (U.S.A)	AA-
124	$	6,000,000	F	83	120.6	American General Life Insurance Company	A+
125	$	1,500,000	F	83	118.9	Lincoln Benefit Life Company	BBB+
126	$	750,000	M	83	98.6	West Coast Life Insurance Company	AA-
127	$	4,000,000	M	83	45.3	John Hancock Life Insurance Company (U.S.A)	AA-
128	$	1,000,000	M	83	91.4	John Hancock Life Insurance Company (U.S.A)	AA-
129	$	2,000,000	F	83	108.5	Lincoln Benefit Life Company	BBB+
130	$	1,000,000	M	83	63.2	ING Life Insurance and Annuity Company	A-
131	$	5,000,000	M	83	84.2	Jefferson-Pilot Life Insurance Company	AA-
132	$	2,700,000	M	83	71.0	John Hancock Life Insurance Company (U.S.A)	AA-
133	$	7,600,000	F	83	107.5	Transamerica Life Insurance Company	AA-
134	$	2,500,000	F	83	72.5	American General Life Insurance Company	A+
135	$	2,500,000	M	83	68.7	AXA Equitable Life Insurance Company	A+
136	$	3,000,000	M	83	68.7	Lincoln National Life Insurance Company	AA-
137	$	500,000	M	83	49.7	Genworth Life Insurance Company	A-
138	$	3,000,000	F	83	52.4	AXA Equitable Life Insurance Company	A+
139	$	1,703,959	M	83	76.9	Jefferson-Pilot Life Insurance Company	AA-
140	$	500,000	M	83	25.8	Great Southern Life Insurance Company	N/A
141	$	1,000,000	M	83	67.3	Hartford Life and Annuity Insurance Company	BBB+
142	$	3,500,000	F	83	117.7	Lincoln Benefit Life Company	BBB+
143	$	10,000,000	F	83	66.4	American National Insurance Company	A
144	$	500,000	M	83	32.7	West Coast Life Insurance Company	AA-
145	$	5,000,000	M	82	75.1	AXA Equitable Life Insurance Company	A+
146	$	500,000	M	82	110.5	Metropolitan Life Insurance Company	AA-
147	$	2,000,000	M	82	48.3	National Life Insurance Company	A
148	$	3,000,000	M	82	48.9	U.S. Financial Life Insurance Company	A+
149	$	4,200,000	F	82	129.2	Transamerica Life Insurance Company	AA-
150	$	1,900,000	M	82	75.6	American National Insurance Company	A
151	$	500,000	M	82	54.5	New York Life Insurance Company	AA+
152	$	500,000	M	82	54.5	New York Life Insurance Company	AA+
153	$	5,000,000	M	82	83.0	AXA Equitable Life Insurance Company	A+
154	$	250,000	M	82	40.6	Jackson National Life Insurance Company	AA
155	$	1,500,000	M	82	84.9	Jefferson-Pilot Life Insurance Company	AA-
156	$	3,500,000	F	82	98.9	AXA Equitable Life Insurance Company	A+
157	$	3,000,000	F	82	104.1	MetLife Investors USA Insurance Company	AA-
158	$	750,000	M	82	91.8	John Hancock Life Insurance Company (U.S.A)	AA-

Page 47

Face Amount

Gender

Age

(ALB)

(mo.)

Insurance Company

S&P Rating

159	$	4,500,000	M	82	83.8	AXA Equitable Life Insurance Company	A+
160	$	2,275,000	M	82	101.1	ING Life Insurance and Annuity Company	A-
161	$	10,000,000	M	82	89.0	AXA Equitable Life Insurance Company	A+
162	$	2,000,000	M	82	95.6	Pacific Life Insurance Company	A+
163	$	3,500,000	M	82	82.0	AXA Equitable Life Insurance Company	A+
164	$	6,217,200	F	82	116.5	Phoenix Life Insurance Company	BB-
165	$	3,000,000	M	82	70.5	Metropolitan Life Insurance Company	AA-
166	$	1,500,000	M	82	33.0	Pacific Life Insurance Company	A+
167	$	2,000,000	F	82	108.4	Jefferson-Pilot Life Insurance Company	AA-
168	$	3,000,000	M	81	77.9	Protective Life Insurance Company	AA-
169	$	1,500,000	M	81	77.9	American General Life Insurance Company	A+
170	$	2,000,000	F	81	127.5	Transamerica Life Insurance Company	AA-
171	$	3,500,000	F	81	102.7	Jefferson-Pilot Life Insurance Company	AA-
172	$	1,000,000	M	81	78.4	Lincoln National Life Insurance Company	AA-
173	$	1,500,000	M	81	65.3	Pacific Life Insurance Company	A+
174	$	5,000,000	M	81	120.8	American General Life Insurance Company	A+
175	$	5,000,000	F	81	85.4	Sun Life Assurance Company of Canada (U.S.)	BBB
176	$	1,995,000	F	81	90.7	Transamerica Life Insurance Company	AA-
177	$	4,000,000	M	81	66.0	Jefferson-Pilot Life Insurance Company	AA-
178	$	1,250,000	F	81	70.7	Columbus Life Insurance Company	AA
179	$	10,000,000	M	81	91.2	New York Life Insurance Company	AA+
180	$	2,300,000	M	81	28.6	American General Life Insurance Company	A+
181	$	2,500,000	F	81	82.0	ING Life Insurance and Annuity Company	A-
182	$	5,000,000	F	81	66.9	Massachusetts Mutual Life Insurance Company	AA+
183	$	5,000,000	M	81	85.8	Transamerica Life Insurance Company	AA-
184	$	2,000,000	M	81	81.1	Ohio National Life Assurance Corporation	AA-
185	$	1,000,000	M	81	81.1	Ohio National Life Assurance Corporation	AA-
186	$	350,000	M	81	44.6	Reassure America Life Insurance Company	AA
187	$	5,000,000	M	81	93.8	Jefferson-Pilot Life Insurance Company	AA-
188	$	5,000,000	M	80	103.6	AXA Equitable Life Insurance Company	A+
189	$	8,000,000	M	80	94.6	AXA Equitable Life Insurance Company	A+
190	$	550,000	M	80	115.6	Genworth Life Insurance Company	A-
191	$	1,680,000	F	80	79.0	AXA Equitable Life Insurance Company	A+
192	$	1,000,000	F	80	109.1	Jefferson-Pilot Life Insurance Company	AA-
193	$	1,250,000	M	80	112.7	Metropolitan Life Insurance Company	AA-
194	$	1,000,000	M	80	77.1	AXA Equitable Life Insurance Company	A+
195	$	1,250,000	F	80	86.5	Principal Life Insurance Company	A+
196	$	1,000,000	M	80	67.4	AXA Equitable Life Insurance Company	A+
197	$	3,000,000	M	80	111.1	John Hancock Life Insurance Company (U.S.A)	AA-
198	$	2,000,000	M	80	50.1	Jefferson-Pilot Life Insurance Company	AA-
199	$	1,750,000	M	80	95.1	AXA Equitable Life Insurance Company	A+
200	$	5,000,000	M	80	84.4	AXA Equitable Life Insurance Company	A+
201	$	250,000	M	80	91.9	American General Life Insurance Company	A+

Page 48

Face Amount

Gender

Age

(ALB)

(mo.)

Insurance Company

S&P Rating

202	$	10,000,000	M	80	126.6	John Hancock Life Insurance Company (U.S.A)	AA-
203	$	1,210,000	M	80	75.5	Lincoln National Life Insurance Company	AA-
204	$	3,000,000	F	80	119.4	West Coast Life Insurance Company	AA-
205	$	7,000,000	M	80	99.2	Genworth Life Insurance Company	A-
206	$	2,000,000	M	79	36.8	Metropolitan Life Insurance Company	AA-
207	$	6,000,000	M	79	137.3	AXA Equitable Life Insurance Company	A+
208	$	130,000	M	79	60.8	Genworth Life Insurance Company	A-
209	$	1,000,000	M	79	138.2	Empire General Life Assurance Corporation	AA-
210	$	2,000,000	F	79	102.5	Pacific Life Insurance Company	A+
211	$	2,000,000	F	79	100.9	Transamerica Life Insurance Company	AA-
212	$	3,000,000	M	79	123.7	Principal Life Insurance Company	A+
213	$	5,000,000	M	79	106.5	AXA Equitable Life Insurance Company	A+
214	$	5,000,000	M	79	106.5	AXA Equitable Life Insurance Company	A+
215	$	500,000	M	79	59.1	Transamerica Life Insurance Company	AA-
216	$	3,000,000	M	78	53.3	Pacific Life Insurance Company	A+
217	$	3,000,000	M	78	53.3	Minnesota Life Insurance Company	A+
218	$	3,000,000	M	78	53.3	Prudential Life Insurance Company	AA-
219	$	3,000,000	M	78	104.0	ING Life Insurance and Annuity Company	A-
220	$	5,000,000	M	78	91.7	Pacific Life Insurance Company	A+
221	$	5,000,000	M	78	91.7	Pacific Life Insurance Company	A+
222	$	4,000,000	M	78	93.1	Jefferson-Pilot Life Insurance Company	AA-
223	$	3,601,500	M	78	108.0	Transamerica Life Insurance Company	AA-
224	$	1,000,000	M	78	104.6	Sun Life Assurance Company of Canada (U.S.)	BBB
225	$	5,000,000	M	78	127.7	Principal Life Insurance Company	A+
226	$	5,000,000	M	78	104.2	John Hancock Life Insurance Company (U.S.A)	AA-
227	$	7,000,000	M	78	99.9	Lincoln Benefit Life Company	BBB+
228	$	476,574	M	78	85.6	Transamerica Life Insurance Company	AA-
229	$	2,250,000	M	78	108.4	Massachusetts Mutual Life Insurance Company	AA+
230	$	4,300,000	F	78	124.6	American National Insurance Company	A
231	$	6,000,000	M	78	121.6	AXA Equitable Life Insurance Company	A+
232	$	5,000,000	F	78	131.6	ING Life Insurance and Annuity Company	A-
233	$	750,000	M	78	83.0	Lincoln National Life Insurance Company	AA-
234	$	3,000,000	M	78	109.9	Principal Life Insurance Company	A+
235	$	5,000,000	M	77	133.4	Jefferson-Pilot Life Insurance Company	AA-
236	$	5,000,000	M	77	91.4	John Hancock Life Insurance Company (U.S.A)	AA-
237	$	500,000	M	77	79.9	John Hancock Life Insurance Company (U.S.A)	AA-
238	$	5,000,000	M	77	102.9	John Hancock Life Insurance Company (U.S.A)	AA-
239	$	1,009,467	M	77	60.6	John Hancock Life Insurance Company (U.S.A)	AA-
240	$	4,000,000	M	77	61.7	MetLife Investors USA Insurance Company	AA-
241	$	2,500,000	M	77	101.8	Massachusetts Mutual Life Insurance Company	AA+
242	$	2,500,000	M	77	101.8	Massachusetts Mutual Life Insurance Company	AA+
243	$	5,000,000	M	77	69.0	John Hancock Life Insurance Company (U.S.A)	AA-
244	$	500,000	F	77	131.5	Columbus Life Insurance Company	AA

Page 49

Face Amount

Gender

Age

(ALB)

(mo.)

Insurance Company

S&P Rating

245	$	3,750,000	M	77	70.7	AXA Equitable Life Insurance Company	A+
246	$	1,000,000	M	77	125.2	Metropolitan Life Insurance Company	AA-
247	$	2,000,000	F	77	69.7	Transamerica Life Insurance Company	AA-
248	$	1,000,000	M	76	123.8	Metropolitan Life Insurance Company	AA-
249	$	2,840,000	M	76	113.5	Transamerica Life Insurance Company	AA-
250	$	750,000	M	76	18.2	U.S. Financial Life Insurance Company	A+
251	$	1,000,000	F	76	89.7	John Hancock Life Insurance Company (U.S.A)	AA-
252	$	1,750,000	M	76	75.8	John Hancock Life Insurance Company (U.S.A)	AA-
253	$	5,000,000	M	76	118.7	Transamerica Life Insurance Company	AA-
254	$	600,000	M	76	99.1	Protective Life Insurance Company	AA-
255	$	3,000,000	M	75	120.3	Protective Life Insurance Company	AA-
256	$	2,000,000	F	75	136.4	Aviva Life Insurance Company	A-
257	$	4,000,000	M	75	81.5	Massachusetts Mutual Life Insurance Company	AA+
258	$	7,000,000	F	75	139.7	Pacific Life Insurance Company	A+
259	$	1,000,000	M	75	98.8	Pacific Life Insurance Company	A+
260	$	490,620	M	75	102.1	Ameritas Life Insurance Corporation	A+
261	$	5,000,000	M	75	73.7	West Coast Life Insurance Company	AA-
262	$	5,000,000	M	74	166.4	Prudential Life Insurance Company	AA-
263	$	3,000,000	M	74	69.8	Aviva Life Insurance Company	A-
264	$	200,000	M	74	85.2	ING Life Insurance and Annuity Company	A-
265	$	8,000,000	M	74	120.1	Metropolitan Life Insurance Company	AA-
266	$	5,000,000	M	74	44.4	Lincoln Benefit Life Company	BBB+
267	$	850,000	M	74	81.2	New York Life Insurance Company	AA+
268	$	4,000,000	F	73	162.3	American General Life Insurance Company	A+
269	$	300,000	M	73	26.5	Lincoln National Life Insurance Company	AA-
270	$	2,000,000	M	73	116.0	American General Life Insurance Company	A+
271	$	3,000,000	F	73	133.6	General American Life Insurance Company	AA-
272	$	500,000	M	72	47.5	Midland National Life Insurance Company	A+
273	$	3,000,000	M	72	91.4	AXA Equitable Life Insurance Company	A+
274	$	1,000,000	M	72	84.8	United of Omaha Life Insurance Company	A+
275	$	2,500,000	M	71	115.6	American General Life Insurance Company	A+
276	$	1,167,000	M	71	40.5	Transamerica Life Insurance Company	AA-
277	$	1,500,000	M	71	130.9	Metropolitan Life Insurance Company	AA-
278	$	3,000,000	M	70	93.9	John Hancock Life Insurance Company (U.S.A)	AA-
279	$	2,000,000	M	70	121.4	New York Life Insurance Company	AA+
280	$	2,000,000	M	70	121.4	New York Life Insurance Company	AA+
281	$	600,000	M	70	104.4	AXA Equitable Life Insurance Company	A+
282	$	500,000	M	69	112.1	Transamerica Life Insurance Company	AA-
283	$	500,000	M	69	112.1	North American Company for Life And Health Insurance	A+
284	$	2,000,000	M	67	134.3	Transamerica Life Insurance Company	AA-
285	$	1,000,000	M	67	134.3	Genworth Life Insurance Company	A-
286	$	2,000,000	M	67	65.9	MetLife Investors USA Insurance Company	AA-
287	$	2,000,000	M	67	65.9	MetLife Investors USA Insurance Company	AA-
288	$	156,538	F	66	126.2	New York Life Insurance Company	AA+
289	$	1,000,000	M	65	63.7	Lincoln National Life Insurance Company	AA-
	$	784,651,923

(1)	The insured’s age is current as of the measurement date.

(2)	The insured’s life expectancy estimate, other than for a small face value insurance policy benefit, is the average of two life expectancy estimates provided by independent third-party medical actuarial underwriting firms actuarially adjusted through the measurement date.

Page 50

ITEM 4.

CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in our reports filed pursuant to the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance the objectives of the control system are met.

As of December 31, 2013, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of our disclosure controls and procedures as such term is defined in Rule 13a-15(e) under the Securities and Exchange Act of 1934, as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with management's evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Securities Exchange Act of 1934 during the period covered by this report that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only with proper authorizations; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our management, under the supervision of and with the participation of the Chief Executive Officer and Chief inancial Officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2013 based on criteria for effective control over financial reporting set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in “ Internal Control—Integrated Framework ”. Based on this assessment, our management concluded that, as of the evaluation date, we maintained effective internal control over financial reporting.

Page 51

PART II. OTHER INFORMATION

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Use of Proceeds – Renewable Secured Debentures

Our Form S-1 registration statement relating to our public offer and sale of “Renewable Secured Debentures” (File Nos. 333-174887 and 333-174887-01) was declared effective by the SEC on January 31, 2012, and our offering of debentures commenced on such date. The debentures are secured in part by a guarantee from our subsidiary GWG Life and an associated grant of a security interest in substantially all of the assets of GWG Life, which guarantee was also registered as a security under the referenced registration statement. Arque Capital Ltd. serves as our managing broker-dealer and underwriter for the offering.

The registration statement covers up to $250 million in principal amount of debentures. From January 31, 2012 through June 30, 2014, we sold a total of $198,030,000 in principal amount of debentures, and incurred associated underwriting commissions, and expenses paid or payable to underwriters in the amount of $9,463,000 of which $4,042,000 was amortized. As of June 30, 2014 we had $160,961,000 of debentures in force plus $1,973,000 of subscriptions in process, less unamortized selling costs of $5,421,000, resulting in aggregate net proceeds of $157,513,000. None of the payments for offering expenses were directly or indirectly made to our directors or officers (or their associates), our affiliates, or to persons owning 10% or more of any class of our equity securities.

Our goal is to use a majority of the net proceeds from the sale of Renewable Secured Debentures to purchase additional life insurance policies in the secondary market. The amount of proceeds we apply towards purchasing additional life insurance policies will depend, among other things, on how long the debentures are offered, the amount of net proceeds that we receive from the sale of debentures being offered, the existence and timing of opportunities to expand our portfolio of insurance policy assets, our cash needs for certain other expenditures we anticipate incurring in connection with this offering and in connection with our business, and the availability of other sources of cash (e.g., our revolving credit facility).

We currently expect to allocate net offering proceeds (assuming the maximum amount of commissions, fees and allowances of 8.00% of the aggregate principal amount of Renewable Secured Debentures sold) as follows, based upon various assumed amounts of gross proceeds that we receive from the proceeds of the offering:

	Gross Offering Proceeds
	$	250,000,000			$	125,000,000			$	62,500,000			$	25,000,000
Net Offering Proceeds		229,000,000	100	%		114,000,000	100	%		56,500,000	100	%		22,000,000	100	%
Purchase Policies		178,620,000	78	%		82,080,000	72	%		38,420,000	68	%		10,560,000	48	%
Payment of Premiums		18,320,000	8	%		11,400,000	10	%		7,910,000	14	%		4,180,000	19	%
Payment of Principal and Interest		16,030,000	7	%		11,400,000	10	%		5,650,000	10	%		4,180,000	19	%
Other Expenditures		16,030,000	7	%		9,120,000	8	%		4,520,000	8	%		3,080,000	14	%

Net offering proceeds not immediately applied to the uses summarized above will be invested short-term investments such as money market funds, commercial paper, U.S. Treasury Bills and similar securities investments pending their use.

The actual use of proceeds from the sale of Renewable Secured Debentures from January 31, 2012 to June 30, 2014 is as follows:

Gross Offering Proceeds	$	173,858,000
Net Offering Proceeds		163,420,000
Held in Short-Term Investments		20,552,000
Net Offering Proceeds Used	$	142,868,000	100	%
Purchase Policies		67,805,000	48	%
Payment of Premiums		25,753,000	18	%
Payment of Principal and Interest		39,091,000	27	%
Other Expenditures		10,219,000	7	%

Page 52

ITEM 6.

EXHIBITS

Exhibit
3.1		Certificate of Amendment of Certificate of Incorporation, dated June 24, 2014 ( filed herewith ).
10.1		Form of Stock Option Agreement used under 2013 Stock Incentive Plan ( incorporated by reference to Exhibit 10.17 to Form S-1/A Registration Statement filed on June 6, 2014 (File No. 333-195505) ).
10.2		Employment Agreement with William Acheson, dated May 30, 2014 ( incorporated by reference to Exhibit 10.19 to Form S-1/A Registration Statement filed on June 6, 2014 (File No. 333-195505) ).
10.3		Amendment No. 1 to Amended and Restated Credit and Security Agreement with DZ Bank AG Deutsche Zentral-Genossenschaftsbank and Autobahn Funding Company LLC, dated May 29, 2014 ( incorporated by reference to Exhibit 10.20 to Form S-1/A Registration Statement filed on June 6, 2014 (File No. 333-195505) ).
31.1		Section 302 Certification of the Chief Executive Officer ( filed herewith ).
31.2		Section 302 Certification of the Chief Financial Officer ( filed herewith ).
32		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 ( filed herewith ).
99.1		Letter from Model Actuarial Pricing Systems, dated July 18, 2014 ( filed herewith ).
101.INS		XBRL Instance Document ( filed herewith ).
101.SCH		XBRL Schema Document ( filed herewith ).
101.CAL		XBRL Calculation Linkbase Document ( filed herewith ).
101.DEF		XBRL Definition Linkbase Document ( filed herewith ).
101.LAB		XBRL Label Linkbase Document ( filed herewith ).
101.PRE		XBRL Presentation Linkbase Document ( filed herewith ).

Page 53

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	GWG HOLDINGS, INC.

Date: August 8, 2014	By:	/s/ Jon R. Sabes
		Chief Executive Officer

Date: August 8, 2014	By:	/s/ William B. Acheson
		Chief Financial Officer

Page 54

Delaware		26-2222607
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Large accelerated filer o	Accelerated filer o
Non-accelerated filer o	Smaller reporting company x

		Page No.
PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements
	Condensed Consolidated Balance Sheets as of June 30, 2014, and December 31, 2013	1
	Condensed Consolidated Statements of Operations for the three months ended June 30, 2014 and 2013	2
	Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2014 and 2013	3
	Condensed Consolidated Statement of Stockholders’ Equity	5
	Notes to Condensed Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29

Item 4.	Controls and Procedures	51

PART II.	OTHER INFORMATION

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	52

Item 6.	Exhibits	53

SIGNATURES		54

	June 30, 2014			December 31, 2013
	(unaudited)
A S S E T S
Cash and cash equivalents	$	23,059,955		$	33,449,793
Restricted cash		2,810,432			5,832,970
Investment in life settlements, at fair value		267,895,692			234,672,794
Other assets		2,822,074			1,424,919
TOTAL ASSETS	$	296,588,153		$	275,380,476

L I A B I L I T I E S & S T O C K H O L D E R S’ E Q U I T Y (D E F I C I T)
LIABILITIES
Revolving credit facility	$	79,000,000		$	79,000,000
Series I Secured notes payable		28,051,113			29,275,202
Renewable Secured Debentures		157,513,267			131,646,062
Interest payable		9,730,193			7,209,408
Accounts payable and accrued expenses		1,714,418			1,343,952
Deferred taxes, net		5,403,604			7,675,174
TOTAL LIABILITIES		281,412,595			256,149,798

CONVERTIBLE, REDEEMABLE PREFERRED STOCK
(par value $0.001; shares authorized 40,000,000; shares issued and outstanding 3,419,767 and 3,368,109; liquidation preference of $25,648,000 and $25,261,000 on June 30, 2014 and December 31, 2013, respectively)		25,309,946			24,722,693

STOCKHOLDERS’ EQUITY
Common stock (par value $0.001: shares authorized 210,000,000; shares issued and outstanding is 4,562,000 on both June 30, 2014 and December 31, 2013)		4,562			4,562
Additional paid-in capital		2,787,494			2,942,000
Accumulated deficit		(12,926,444	)		(8,438,577	)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)		(10,134,388	)		(5,492,015	)

TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)	$	296,588,153		$	275,380,476

	Three Months Ended						Six Months Ended
	June 30, 2014			June 30, 2013			June 30, 2014			June 30, 2013
REVENUE
Gain on life settlements, net	$	5,484,889		$	7,733,245		$	11,001,094		$	16,073,601
Interest and other income		6,380			3,274,323			13,747			3,441,994
TOTAL REVENUE		5,491,269			11,007,568			11,014,841			19,515,595

EXPENSES
Employee compensation and benefits		1,178,819			1,063,923			2,147,564			3,001,343
Legal and professional fees		419,337			351,910			826,339			789,200
Interest expense		6,608,043			4,941,942			12,934,591			9,409,157
Other expenses		1,188,479			1,091,132			1,865,784			2,124,277
TOTAL EXPENSES		9,394,678			7,448,907			17,774,278			15,323,977

INCOME (LOSS) BEFOREINCOME TAXES		(3,903,409	)		3,558,661			(6,759,437	)		4,191,618
INCOME TAX EXPENSE (BENEFIT)		(1,316,712	)		1,801,971			(2,271,570	)		2,367,794

NET INCOME (LOSS)	$	(2,586,697	)	$	1,756,690		$	(4,487,867	)	$	1,823,824

Accretion of preferred stock to liquidation value		(101,271	)		(208,877	)		(226,984	)		(466,640	)
LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$	(2,687,968	)	$	1,547,813		$	(4,714,851	)	$	1,357,184
NET INCOME (LOSS) PER SHARE
Basic	$	(0.59	)	$	0.31		$	(1.03	)	$	0.28
Diluted	$	(0.59	)	$	0.21		$	(1.03	)	$	0.19

WEIGHTED AVERAGE SHARES OUTSTANDING
Basic		4,562,000			4,984,994			4,562,000			4,774,102
Diluted		4,562,000			7,511,099			4,562,000			7,290,253

	Common			Common Stock			Additional Paid-in			Accumulated			Total
	Shares			(par)			Capital			Deficit			Equity

Balance, December 31, 2012		4,994,500			4,995			6,976,838			(8,243,622	)		(1,261,789	)

Net loss		-			-			-			(194,955	)		(194,955	)

Repurchase of common stock		(432,500	)		(433	)		(3,251,967	)		-			(3,252,400	)

Issuance of stock options		-			-			23,753			-			23,753

Accretion of preferred stock to liquidation value		-			-			(806,624	)		-			(806,624	)

Balance, December 31, 2013		4,562,000		$	4,562		$	2,942,000		$	(8,438,577	)	$	(5,492,015	)

Net loss		-			-			-			(4,487,867	)		(4,487,867	)

Issuance of stock options			-		-			72,478			-			72,478

Accretion of preferred stock to liquidation value			-		-			(226,984	)		-			(226,984	)

Balance, June 30, 2014		4,562,000			4,562			2,787,494			(12,926,444	)		(10,134,388	)

	As of June 30, 2014						As of December 31, 2013
Years Ending December 31,	Number of Contracts		Estimated Fair Value		Face Value		Number of Contracts		Estimated Fair Value		Face Value
2014		-	$	-	$	-		-	$	-	$	-
2015		3		4,781,000		6,000,000		4		5,065,000		6,750,000
2016		11		11,035,000		16,450,000		8		8,174,000		13,750,000
2017		26		33,191,000		59,716,000		25		33,345,000		63,916,000
2018		29		35,358,000		70,017,000		33		37,243,000		80,318,000
2019		44		44,279,000		109,795,000		34		32,844,000		89,295,000
2020		38		35,833,000		91,224,000		34		27,741,000		75,644,000
Thereafter		138		103,419,000		431,450,000		125		90,261,000		410,975,000
Totals		289		267,896,000		784,652,000		263	$	234,673,000	$	740,648,000

Years Ending December 31,
Six months ending December 31 ,2014	$	12,213,000
2015		26,693,000
2016		29,402,000
2017		32,847,000
2018		35,767,000
	$	136,922,000

	As of June 30, 2014			As of December 31, 2013
Weighted average age of insured		82.5			82.1
Weighted average life expectancy, months*		82.2			87.0
Average face amount per policy	$	2,715,000		$	2,816,000
Discount rate		11.56	%		11.69	%
* Standard life expectancy as adjusted for insured’s specific circumstances.

	Changes in fair value of life insurance policies
Change in life expectancy estimates	plus 8 months				minus 8 months			plus 4 months				minus 4 months

June 30, 2014		$	(38,249,000	)		$	40,171,000		$	(19,368,000	)		$	19,856,000

December 31, 2013		$	(34,382,000	)		$	36,152,000		$	(17,417,000	)		$	17,865,000

Change in discount rate	plus 2%				minus 2%		plus 1%			minus 1%

June 30, 2014		$	(24,381,000	)	$	28,624,000	$	(12,666,000	)	$	13,723,000

December 31, 2013		$	(22,944,000	)	$	27,063,000	$	(11,933,000	)	$	12,959,000

Month issued	Warrants issued		Fair value per share		Risk free rate			Volatility			Term
December 2011		68,937	$	0.22		0.42	%		25.25	%	3 years
March 2012		38,130	$	0.52		0.38	%		36.20	%	3 years
June 2012		161,841	$	1.16		0.41	%		47.36	%	3 years
July 2012		144,547	$	1.16		0.41	%		47.36	%	3 years
September 2012		2,500	$	0.72		0.31	%		40.49	%	3 years
		415,954

●	changing its corporate name, offices, and jurisdiction of incorporation
●	changing any deposit accounts or payment instructions to insurers;
●	changing any operating policies and practices such that it would be reasonably likely to adversely affect the collectability of any asset in any material respect;
●	merging or consolidating with, or selling all or substantially all of its assets to, any third party;
●	selling any collateral or creating or permitting to exist any adverse claim upon any collateral;
●	engaging in any other business or activity than that contemplated by the Agreement;
●	incurring or guaranteeing any debt for borrowed money;
●	amending the Company’s certificate of incorporation or bylaws, making any loans or advances to, investments in, or paying any dividends to, any person unless both before and after any such loan, advance, investment or dividend there exists no actual event of default, potential event of default or termination event;
●	removing an independent director on the board of directors except for cause or with the consent of the lender; or
●	making payment on or issuing any subsidiary secured notes or debentures, or amending any agreements respecting such notes or debentures, if an event of default, potential event of default or termination event exists or would arise from any such action.

●	Up to 33% of the holder’s unredeemed shares one year after issuance:
●	Up to 66% of the holder’s unredeemed shares two years after issuance; and
●	Up to 100% of the holder’s unredeemed shares three years after issuance.

Grant Date	Exercise Price		Shares		Vesting	Binomial Value		Forfeiture Factor		Compensation Expense
9/5/2013	$	7.52		143,750	Immediate		0.360		0.8700		45,023
9/5/2013	$	8.28		25,000	Immediate		0.360		0.8700		7,830
9/5/2013	$	7.52		45,839	1 year		0.360		0.8500		14,027
9/5/2013	$	8.28		2,834	1 year		0.360		0.8500		867
9/5/2013	$	7.52		45,833	2 years		0.600		0.7225		19,869
9/5/2013	$	8.28		2,833	2 years		0.600		0.7225		1,228
9/5/2013	$	7.52		45,828	3 years		0.820		0.6141		23,078
9/5/2013	$	8.28		2,833	3 years		0.820		0.6141		1,427
9/30/2013	$	7.52		4,000	Immediate		0.660		0.8700		2,297
10/28/2013	$	7.52		6,000	Immediate		0.660		0.8700		3,445
10/28/2013	$	7.52		24,000	1 year		0.660		0.8500		13,464
10/28/2013	$	7.52		24,000	2 years		0.920		0.7225		15,953
10/28/2013	$	7.52		18,000	3 years		1.140		0.6141		12,602
11/11/2013	$	7.52		4,167	1 year		0.660		0.8500		2,338
11/11/2013	$	7.52		4,167	2 years		0.920		0.7225		2,770
11/11/2013	$	7.52		4,166	3 years		1.140		0.6141		2,917
12/12/2013	$	7.52		30,000	Immediate		0.660		0.8700		17,226
4/1/2014	$	7.46		1,935	Immediate		0.468		0.8700		788
4/1/2014	$	7.46		11,008	1 year		1.028		0.8500		9,619
4/1/2014	$	7.46		10,999	2 years		1.240		0.7225		9,854
4/1/2014	$	7.46		10,993	3 years		1.292		0.6141		8,722
4/7/2014	$	7.46		3,334	1 year		1.028		0.8500		2,913
4/7/2014	$	8.20		3,334	1 year		1.028		0.8500		2,913
4/7/2014	$	7.46		3,333	2 years		1.240		0.7225		2,986
4/7/2014	$	8.20		3,333	2 years		1.240		0.7225		2,986
4/7/2014	$	7.46		3,333	3 years		1.292		0.6141		2,645
4/7/2014	$	8.20		3,333	3 years		1.292		0.6141		2,645
4/28/2014	$	7.46		5,000	Immediate		0.468		0.8700		2,036
4/28/2014	$	7.46		2,500	1 year		1.028		0.8500		2,185
4/28/2014	$	7.46		2,500	2 years		1.240		0.7225		2,240
4/28/2014	$	7.46		2,500	3 years		1.292		0.6141		1,984
5/27/2014	$	7.46		2,500	Immediate		0.468		0.8700		1,018
5/27/2014	$	7.46		10,000	1 year		1.028		0.8500		8,738
5/27/2014	$	7.46		10,000	2 years		1.240		0.7225		8,959
5/27/2014	$	7.46		10,000	3 years		1.292		0.6141		7,934
6/20/2014	$	7.46		3,000	Immediate		0.468		0.8700		1,221
6/20/2014	$	7.46		6,000	1 year		1.028		0.8500		5,243
6/20/2014	$	7.46		6,000	2 years		1.240		0.7225		5,375
6/20/2014	$	7.46		3,000	3 years		1.292		0.6141		2,380
				551,185

	Three Months Ended						Six Months Ended
	June 30, 2014			June 30, 2013			June 30, 2014			June 30, 2013

CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$	(2,586,697	)	$	1,756,690		$	(4,487,867	)	$	1,823,824
Adjustments to reconcile net income (loss) to net cash flows from operating activities:
Gain on life settlements		(10,852,425	)		(7,449,180	)		(22,211,338	)		(18,943,905	)
Amortization of deferred financing and issuance costs		1,354,007			837,133			1,707,664			1,930,880
Deferred income taxes		(1,316,712	)		1,802,920			(2,271,570	)		2,366,794
Convertible, redeemable preferred stock dividends payable		196,991			178,235			389,331			261,937
(Increase) decrease in operating assets:
Other assets		(997,073	)		(4,164,004	)		(1,248,919	)		(3,614,132	)
Increase (decrease) in operating liabilities:
Accounts payable and accrued expenses		1,890,337			402,739			3,168,163			1,694,797

NET CASH FLOWS USED IN OPERATING ACTIVITIES		(12,311,572	)		(6,635,467	)		(24,954,536	)		(14,479,805	)

CASH FLOWS FROM INVESTING ACTIVITIES
Investment in life settlements		(2,608,232	)		(2,972,944	)		(10,879,435	)		(12,885,993	)
Proceeds from settlement of life settlements		68,500			1,382,152			68,500			2,872,152
NET CASH FLOWS USED IN INVESTING ACTIVITIES		(2,539,732	)		(1,590,792	)		(10,810,935	)		(10,013,841	)

CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from revolving credit facility		-			-			-			8,000,000
Payments for redemption of Series I Secured notes payable		(670,621	)		(2,423,052	)		(1,538,924	)		(3,930,876	)
Proceeds from issuance of renewable secured debentures		14,868,830			18,588,867			33,234,487			42,439,661
Payments for redemption and issuance of renewable secured debentures		(4,393,523	)		(3,033,303	)		(9,322,411	)		(5,336,571	)
Proceeds from restricted cash		43,330			2,160,333			3,022,537			(2,370,775	)
Repurchase of common stock		-			(3,252,400	)		-			(3,252,400	)
Issuance (redemptions) of convertible, redeemable preferred stock		(20,056	)		(125,135	)		(20,056	)		(311,804	)
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		9,827,960			11,915,310			25,375,633			35,237,235

NET INCREASE IN CASH AND CASH EQUIVALENTS		(5,023,344	)		3,689,051			(10,389,838	)		10,743,589

CASH AND CASH EQUIVALENTS
BEGINNING OF PERIOD		28,083,299			34,551,582			33,449,793			27,497,044
END OF PERIOD	$	23,059,955		$	38,240,633		$	23,059,955		$	38,240,633

For the six months ended June 30, 2014	Parent			Guarantor Sub			Non-Guarantor Sub			Eliminations			Consolidated
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$	(4,487,867	)	$	5,004,443		$	6,827,686		$	(11,832,129	)	$	(4,487,867	)
Adjustments to reconcile net loss to cash:
(Equity) loss of subsidiaries		(5,004,443	)		(6,827,686	)		-			11,832,129			-
Life settlements – change in fair value		-			-			(22,211,338	)		-			(22,211,338	)
Amortization of deferred financing and issuance costs		1,727,610			301,104			(321,050	)					1,707,664
Deferred income taxes		(2,271,570	)		-			-						(2,271,570	)
Preferred stock issued for dividends		389,331
(Increase) in operating assets:
Other assets		(26,622,350	)		(24,654,818	)		(300,000)			50,328,249			(1,248,919	)
Increase in operating liabilities:
Accounts payable and other accrued expenses		1,971,543			302,402			894,218			-			3,168,163
NET CASH FLOWS USED IN OPERATING ACTIVITIES		(34,297,746	)		(25,874,555	)		(15,110,484	)		50,328,249			(24,954,536	)

CASH FLOWS FROM INVESTING ACTIVITIES
Investment in life settlements		-			-			(10,879,435	)		-			(10,879,435	)
Proceeds from settlement of life settlements		-			-			68,500			-			68,500
NET CASH FLOWS USED IN INVESTING ACTIVITIES		-			-			(10,810,935	)		-			(10,810,935	)

CASH FLOWS FROM FINANCING ACTIVITIES
Payments for redemption of Series I Secured notes payable		-			(1,538,924	)		-			-			(1,538,924	)
Proceeds from issuance of debentures		33,234,487			-			-			-			33,234,487
Payments for issuance costs and redemption of Renewable Secured Debentures		(9,322,411	)		-			-			-			(9,322,411	)
Proceeds from restricted cash		-			855,000			2,167,537			-			3,022,537
Payments for redemption of preferred stock		(20,056	)		-			-			-			(20,056	)
Issuance of member capital		-			26,574,367			23,753,882			(50,328,249	)		-
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		23,892,020			25,890,443			25,921,419			(50,328,249	)		25,375,633

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(10,405,723	)		15,888			-			-			(10,389,838	)

CASH AND CASH EQUIVALENTS
BEGINNING OF THE PERIOD		32,711,636			738,157			-			-			33,449,793

END OF THE PERIOD	$	22,305,910		$	754,045		$	-		$	-		$	23,059,955

For the six months ended June 30, 2013	Parent			Guarantor Sub			Non-Guarantor Sub			Eliminations			Consolidated

CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$	1,823,824		$	10,117,924		$	10,848,388		$	(20,966,312	)	$	1,823,824
Adjustments to reconcile net income to cash:
Equity income of subsidiaries		(982,826	)		(867,920	)		-			1,850,746			-
(Gain) loss on life settlements		-			-			(18,943,905	)		-			(18,943,905	)
Amortization of deferred financing and issuance costs		737,959			434,431			758,490			-			1,930,880
Deferred income taxes		2,366,794			-			-			-			2,366,794
Preferred stock issued for dividends		261,937			-			-			-			261,937
(Increase) decrease in operating assets:
Other assets		(27,278,091	)		(24,355,215	)		(3,330,802	)		51,349,976			(3,614,132	)
Increase (decrease) in operating liabilities:
Accounts payable and other accrued expenses		1,485,107			119,503			90,187			-			1,694,797
NET CASH FLOWS USED IN OPERATING ACTIVITIES		(21,585,296	)		(14,551,277	)		(10,577,642	)		32,234,410			(14,479,805	)

CASH FLOWS FROM INVESTING ACTIVITIES
Investment in life settlements		-			-			(12,885,993	)		-			(12,885,993	)
Proceeds from settlement of life settlements		-			-			2,872,152			-			2,872,152
NET CASH FLOWS USED IN INVESTING ACTIVITIES		-			-			(10,013,841	)		-			(10,013,841	)

CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from revolving credit facility		-			-			8,000,000			-			8,000,000
Payments for redemption of Series I Secured notes payable		-			(3,930,876	)		-			-			(3,930,876	)
Proceeds from issuance of debentures		42,439,661			-			-			-			42,439,661
Payments from issuance of debentures		(2,140,704	)		-			-			-			(2,140,704	)
Payments from redemption of debentures		(3,195,867	)		-			-			-			(3,195,867	)
Proceeds (payments) from restricted cash		-			(752,800	)		(1,617,975	)		-			(2,370,775	)
Issuance of member capital		-			18,024,952			14,209,458			(32,234,410	)		-
Repurchase of common stock		(3,252,400	)		-			-			-			(3,252,400	)
Payments for redemption of preferred stock		(311,804	)		-			-			-			(311,804	)
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		33,538,886			13,341,276			20,591,483			(32,234,410	)		35,237,235

NET INCREASE IN CASH AND CASH EQUIVALENTS		11,953,590			(1,210,001	)		-			-			10,743,589

CASH AND CASH EQUIVALENTS
BEGINNING OF THE PERIOD		25,035,579			2,461,465			-			-			27,497,044

END OF THE PERIOD	$	36,989,169		$	1,251,464		$	-		$	-		$	38,240,633

For the three months ended June 30, 2014	Parent			Guarantor Sub			Non-Guarantor Sub			Eliminations			Consolidated

CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$	(2,586,697	)	$	2,372,886		$	3,790,677		$	(6,163,563	)	$	(2,586,697	)
Adjustments to reconcile net loss to cash:
(Equity) loss of subsidiaries		(2,372,886	)		(3,790,677	)		-			6,163,563			-
Life settlements – change in fair value		-			-			(10,852,425	)		-			(10,852,425	)
Amortization of deferred financing and issuance costs		880,374			134,158			339,475			-			1,354,007
Deferred income taxes		(1,316,712	)		-			-			-			(1,316,712	)
Preferred stock issued for dividends		196,991			-			-			-			196,991
(Increase) in operating assets:
Other assets		(10,674,637	)		(9,406,461	)		(300,000	)		19,384,025			(997,073	)
Increase in operating liabilities:
Accounts payable and other accrued expenses		1,257,758			72,959			559,620			-			1,890,337
NET CASH FLOWS USED IN OPERATING ACTIVITIES		(14,615,809	)		(10,617,135	)		(6,462,653	)		19,384,025			(12,311,572	)

CASH FLOWS FROM INVESTING ACTIVITIES
Investment in life settlements		-			-			(2,608,232	)		-			(2,608,232	)
Proceeds from settlement of life settlements		-			-			68,500			-			68,500
NET CASH FLOWS USED IN INVESTING ACTIVITIES		-			-			(2,539,732	)		-			(2,539,732	)

CASH FLOWS FROM FINANCING ACTIVITIES
Payments for redemption of Series I Secured notes payable		-			(670,621	)		-			-			(670,621	)
Proceeds from issuance of debentures		14,868,830			-			-			-			14,868,830
Payments for issuance costs and redemption of Renewable Secured Debentures		(4,393,523	)		-			-			-			(4,393,523	)
Proceeds from restricted cash		-			(215,000	)		258,330			-			43,330
Issuance of member capital		-			10,639,970			8,744,055			(19,384,025	)		-
Payments for redemption of preferred stock		(20,056	)		-			-			-			(20,056	)
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		10,455,251			9,754,349			9,002,385			(19,384,025	)		9,827,960

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(4,160,558	)		(862,786	)		-			-			(5,023,344	)

CASH AND CASH EQUIVALENTS
BEGINNING OF THE PERIOD		26,466,468			1,616,831			-			-			28,083,299

END OF THE PERIOD	$	22,305,910		$	754,045		$	-		$	-		$	23,059,955

	Vested			Un-vested			Total
Balance as of December 31, 2013		195,000			210,250			405,250
Granted during the year		12,435			105,500			117,935
Exercised during the year		-			-			-
Forfeited during the year		(10,000	)		(22,750	)		(32,750	)
Expired during the year		-			-			-
Balance as of June 30, 2014		197,435			293,000			490,435

December 31, 2013	Parent			Guarantor Subsidiary		Non-Guarantor Subsidiaries		Eliminations			Consolidated

A S S E T S
Cash and cash equivalents	$	32,711,636		$	738,157	$	-	$	-		$	33,449,793
Restricted cash		-			1,420,000		4,412,970		-			5,832,970
Investment in life settlements, at fair value		-			-		234,672,794		-			234,672,794
Other assets		381,883			484,510		558,526		-			1,424,919
Investment in subsidiaries		129,839,241			159,798,490		-		(289,637,731	)		-

TOTAL ASSETS	$	162,932,760		$	162,441,157	$	239,644,290	$	(289,637,731	)	$	275,380,476

L I A B I L I T I E S & S T O C K H O L D E R S' E Q U I T Y (D E F I C I T)
LIABILITIES
Revolving credit facility	$	-		$	-	$	79,000,000	$	-		$	79,000,000
Series I Secured notes payable		-			29,275,202		-		-			29,275,202
Renewable Secured Debentures		131,646,062			-		-		-			131,646,062
Interest payable		3,806,820			3,065,465		337,123		-			7,209,408
Accounts payable and other accrued expenses		574,026			261,249		508,667		-			1,343,952
Deferred taxes		7,675,174			-		-		-			7,675,174
TOTAL LIABILITIES		143,702,082			32,601,916		79,845,800		-			256,149,798

CONVERTIBLE, REDEEMABLE PREFERRED STOCK		24,722,693			-		-		-			24,722,693

STOCKHOLDERS’ EQUITY (DEFICIT)
Member capital		-			129,839,241		159,798,490		(289,637,731	)		-
Common stock		9,124			-		-		-			9,124
Additional paid-in capital		2,937,438			-		-		-			2,937,438
Accumulated deficit		(8,438,577	)		-		-		-			(8,438,577	)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)		(5,492,015	)		129,839,241		159,798,490		(289,637,731	)		(5,492,015	)

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$	162,932,760		$	162,441,157	$	239,644,290	$	(289,637,731	)	$	275,380,476

For the three months ended June 30, 2013	Parent			Guarantor Subsidiary			Non-Guarantor Subsidiaries		Eliminations			Consolidated
REVENUE
Contract servicing fees	$	-		$	536,100		$	-	$	(536,100	)	$	-
Gain on life settlements, net		-			-			7,733,245		-			7,733,245
Interest and other income		3,259,362			841,286			14,610		(840,935	)		3,274,323

TOTAL REVENUE		3,259,362			1,377,386			7,747,855		(1,377,035	)		11,007,568

EXPENSES
Origination and servicing fees		-			-			536,100		(536,100	)		-
Employee compensation and benefits		666,354			397,569			-		-			1,063,923
Legal and professional fees		272,794			79,116			-		-			351,910
Interest expense		2,655,430			942,686			1,343,826		-			4,941,942
Other expenses		649,112			429,520			853,435		(840,935	)		1,091,132

TOTAL EXPENSES		4,243,690			1,848,891			2,733,361		(1,377,035	)		7,448,907

INCOME (LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES		(984,328	)		(471,505	)		5,014,494		-			3,558,661

EQUITY IN INCOME OF SUBSIDIARY		4,543,289			5,014,494			-		(9,557,783	)		-

NET INCOME BEFORE INCOME TAXES		3,558,961			4,542,989			5,014,494		(9,557,783	)		3,558,661

INCOME TAX EXPENSE (BENEFIT)		1,802,271			(300	)		-		-			1,801,971
NET LOSS	$	1,756,690		$	4,543,289		$	5,014,494	$	(9,557,783	)	$	1,756,690

	June 30,		December 31,
	2014		2013
Life insurance company	%		%

Company A		15.72		16.58
Company B		10.95		11.34

1.	I have reviewed this quarterly report on Form 10-Q of GWG Holdings, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ Jon R. Sabes
	Jon R. Sabes
	Chief Executive Officer

	August 8, 2014

	/s/ William B. Acheson
	William B. Acheson
	Chief Financial Officer

	August 8, 2014

	1156 West Shure Dr., Suite 130 Arlington Heights, IL 60004 +1 (847) 483-9402

July 18, 2014

	GWG Portfolio as of 6/30/2014
Number of Policies		289
Total Net Death Benefit ($)		784,651,923
Discount Rate		11.56	%	7.21	%	12.00	%	15.00	%
Expected Net Present Value ($)		267,895,692		336,987,135		262,198,841		228,133,851
Stochastic Analysis – 10,000 Scenarios
95th Percentile Net Present Value ($)		239,410,780		308,095,084		233,793,755		200,578,740
95% CTE Net Present Value ($)		232,813,422		300,870,152		227,245,966		194,099,914